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 ABSTRACT 
Notch3 Signaling Promotes Adhesion and Tumor Progression in a Murine Epithelial Ovarian 
Cancer Model 
Jessica C. Price 
Ovarian cancer is the 5th leading cause of cancer death in women in the United States and is the 
most fatal gynecological malignancy. High grade serous ovarian cancer (HGSC) is the most common and 
deadly type of ovarian cancer largely due to the rapid metastasis throughout the peritoneum (abdominal 
cavity wall and organ lining). Metastatic spread of ovarian cancer usually occurs before diagnosis and can 
lead to bowel obstruction, organ failure, ascites, cachexia, infection and sepsis, and pulmonary embolism 
all causing death. Current methods to detect early stage ovarian cancer do not increase overall survival. A 
better understanding of the metastatic ability of ovarian cancers and the mechanism of cancer cell 
dissemination are critical to the development of new treatments for this devastating disease. In particular, 
investigation of pathways that affect early metastasis may indicate treatments that will lower disease burden 
and may suggest biomarkers of recurrent and/or chemotherapy resistant disease.  
Notch3 expression correlates with worse prognosis, chemotherapy resistance, and increased 
tumorigenic cell behaviors in HGSC. Here, we demonstrate that Notch3 acts to promote early stages of 
metastasis in a model of HGSC using the murine ID8 IP2 ovarian surface epithelial cell line. ID8 IP2 cells 
have little to no endogenous Notch3 expression and model metastatic disease when introduced 
intraperitoneally. We investigated the role of Notch3 by ectopically expressing the intracellular domain of 
murine Notch3 to induce constitutive Notch3 signaling in ID8 IP2 cells and verified Notch signal activation 
by target gene assessment.  Induction of Notch3 signaling in ID8 IP2 reduced survival and accelerated 
disease burden, as measured by ascites accumulation, after intraperitoneal introduction of cells into nude 
mice. We interrogated downstream targets in Notch3 activated cells by RNA-Seq and found that Notch3 
induced a significant enrichment of adhesion and extracellular matrix pathways. Notch3 active cells showed 
increased ITGA1 expression and increased adhesion on collagens I and IV in vitro, suggesting that 
increased adhesion to collagen-rich peritoneal surfaces drives the observed increase in tumor burden. 
Notch3 active cells showed reduced migration on surfaces coated with multiple types of extracellular matrix 
 and no detectable increase in invasion through extracellular matrix, indicating that Notch3 effects may be 
specific to the initial adhesion of tumor cells and not the later stages of metastasis.  
 These results demonstrate that Notch3 upregulates the expression of specific adhesion genes in 
ovarian cancer cells and this promotes increased attachment to the collagen-rich extracellular matrix. The 
implications of this study are that oncogenic Notch signal activation, as documented in human disease, 
may promote dissemination and metastasis of primary and/or recurrent HGSC by increasing attachment to 
the peritoneal lining.  
 
 i 
TABLE OF CONTENTS 
List of Figures and Tables ........................................................................................................................ iii	
Acknowledgements ................................................................................................................................... vi	
Chapter 1 ..................................................................................................................................................... 1	
Introduction ................................................................................................................................................. 1	
Ovarian Cancer ............................................................................................................................... 1	
The Notch signaling pathway .......................................................................................................... 5	
The role of Notch3 signaling in high grade serous ovarian cancer .................................................. 9	
Chapter 2 ................................................................................................................................................... 12	
Materials and Methods ............................................................................................................................. 12	
Chapter 3 ................................................................................................................................................... 24	




Chapter 4 ................................................................................................................................................... 48	
Notch3 Intracellular Domain Affects Ascites Accumulation and Reduces Survival in Tumor 




Chapter 5 ................................................................................................................................................... 64	




Chapter 6 ................................................................................................................................................... 78	






Chapter 7 ................................................................................................................................................... 91	







LIST OF FIGURES AND TABLES 
 
Figure1.1 Canonical Notch receptor signaling leads to the activation of gene transcription ........................ 7	
Figure 3.1 Human high grade serous ovarian cancer histology and gross tumor appearance. ................. 28	
Figure 3.2 OVCAR5 luciferase intraperitoneally injected mice display peritoneal tumor burden. .............. 31	
Figure 3.3 ID8 luciferase intraperitoneal injected mice show tumor burden at 60 days. ............................ 34	
Figure 3.4 ID8 luciferase subcutaneous injected mice show tumor burden at 60 days ............................. 35	
Figure 3.5 Time course analysis of tumor burden in ID8 luciferase intraperitoneally injected mice ........... 37	
Figure 3.6 The ID8 IP2 luciferase line produces tumors when injected intraperitoneally in less time than the 
ID8 .............................................................................................................................................................. 41	
Figure 3.7 ID8 IP2 luc tumors may lose their bioluminescence when implanted intraperitoneally in vivo in 
immunocompetent mice ............................................................................................................................. 42	
Figure 3.8 Bioluminescent evaluation of ID8 IP2 luciferase tumors implanted in C57BL/6 does not correlate 
with tumor burden but abdominal circumference measurement relates to ascites accumulation .............. 43	
Figure 3.9 ID8 IP3 luciferase lines do not generate peritoneal tumors that display consistent 
bioluminescence with whole mouse live imaging ....................................................................................... 45	
Figure 4.1 NOTCH3 is not notably expressed in ID8 IP2 ovarian tumorigenic cells .................................. 51	
Figure 4.2 Notch3 expression and signal activation is present in lentivirally infected ID8 IP2 luc cells ..... 54	
Table 4.1 Notch3 and downstream target activation for each lentiviral infected line set shows consistent 
activation of the Notch pathway. ................................................................................................................ 55	
Figure 4.3 There is no significant change in the growth and viability of Notch3IC ID8 IP2 luc ovarian cancer 
cells in vitro ................................................................................................................................................. 58	
Figure 4.4 Notch3IC causes a reduction in mouse survival and an increase in disease burden in vivo .... 61	
Figure 5.1 A Notch3 signaling signature is enriched in the RNA-Seq analysis of ID8 IP2 luc Notch3IC 
compared to Control ................................................................................................................................... 66	
Table 5.1 Most significant pathways by p value for each database sampled by DAVID show many pathways 
related to adhesion and ECM are regulated by active Notch3 ................................................................... 68	
Table 5.2 Notch3 intracellular domain significantly upregulates many significant adhesion and extracellular 
matrix pathways identified by DAVID analysis ........................................................................................... 70	
  
iv 
Figure 5.2 Expression of collagen genes for all samples subjected to RNA-Seq show a subset of enriched 
collagen genes induced by Notch3 intracellular domain ............................................................................ 72	
Figure 5.3 Integrin receptor genes expression for all samples assessed by RNA-Seq show a set of enriched 
integrin genes induced by Notch3 intracellular domain activity .................................................................. 73	
Table 5.3 Adhesion and extracellular matrix pathways are significantly enriched in Notch3IC cells when 
analyzed by GSEA pathway analysis ......................................................................................................... 75	
Figure 5.4 GSEA data analysis of Notch3IC compared to Control data shows collagen genes among the 
top 20 enriched pathways, and as the most significantly enriched of the adhesion and extracellular matrix 
pathways .................................................................................................................................................... 76	
Figure 6.1 Integrin receptor components altered in Notch3IC compared to Control determined by RNA-Seq
.................................................................................................................................................................... 81	
Figure 6.2 Notch3IC display increased surface levels of ITGΑ1 by flow cytometry ................................... 83	
Figure 6.3 ID8 IP2 luc Notch3IC more adherent to collagens than Control ............................................... 85	
Figure 6.4 Active Notch3 causes reduced migration of ID8 IP2 luciferase on extracellular matrix ............ 87	
Figure 6.5 There is no significant change in adhesion with Notch3 activation in ID8 IP2 luciferase cells .. 89	
Figure 7.1 Attachment of ovarian cancer cells to the ECM of the peritoneum. .......................................... 94	
Figure 7.2 Proposed model of the influence of Notch3 on ovarian cancer cell metastatic attachment to the 
peritoneum ................................................................................................................................................. 96	
Figure 7.3 Fallopian derived tumorigenic cell lines express varying levels of NOTCH3 ............................ 98	
Tables A4.1 and A4.2. Notch pathway primer sequences for primers used in Semiquantitative RT-PCR and 
RT-qPCR experiments ............................................................................................................................. 121	
Figure A4.1 NOTCH3 is present in ovarian cancer cell lines that are retrovirally infected with full length 
Notch3HA ................................................................................................................................................. 122	
Figure A4.2 Properties of ID8 IP2 luc Notch3IC and Control subjected to FACS display different phenotypes 
than for non-sorted populations of lentivirally infected cells ..................................................................... 123	
Figure A4.3 Cachexia criteria and in vivo data analysis excluding cachectic tumor bearing mice ........... 124	
  
v 
Figure A4.4 Peritoneal wall tumor burden, and right ovary and uterine horn tumor burden in mice sacrificed 
at 8 weeks does not show a significant difference between Notch3IC and Control despite higher levels of 
Notch3IC bioluminescent signal ............................................................................................................... 125	
Figure A5.1 Selected list of the most upregulated genes in Notch3IC compared to Control ID8 IP2 luciferase
.................................................................................................................................................................. 126	
Figure 5.2 Selected list of the most highly downregulated genes in Notch3IC compared to Control ID8 IP2 
luciferase .................................................................................................................................................. 127	
Figure A5.3 Significantly upregulated genes in adhesion and ECM pathways identified by DAVID pathway 
analysis show many integrin and collagen genes among others ............................................................. 130	
Table A5.1 DAVID pathway enrichment analysis of downregulated genes identified by RNA-Seq analysis 
of Notch3IC compared to Control. ............................................................................................................ 131	
Table A5.2 Adhesion pathways found to be downregulated in pathway analysis are related to cell to cell 
adhesion despite upregulation of many adhesion pathways. ................................................................... 131	
Table A5.3 Genes identified in downregulated pathways related to adhesion ......................................... 131	
Table A5.4 GSEA top enriched pathways show a variety of pathways which includes a pathway related to 
collagen genes ......................................................................................................................................... 132	
Table A5.5 Top enriched pathways identified by GSEA analysis of downregulated genes show similarity to 
adhesion pathways significantly enriched in DAVID analysis for Notch3 intracellular domain regulated 
genes ........................................................................................................................................................ 133	
Table A5.6 Collagen genes are found to be enriched in GSEA analysis of Notch3 intracellular domain 
regulated genes. ....................................................................................................................................... 134	
Figure A5.4 GSEA assessment identifies the NABA_COLLAGENS pathway as enriched in RNA-Seq 
analysis of Notch3 intracellular domain regulated genes ......................................................................... 135	
Figure A6.1 ID8 IP2 luciferase lines are differentially adherent to distinct extracellular matrices. ........... 136	







 I would like to thank my thesis advisor Dr. Jan Kitajewski for inviting me into his lab and providing 
me the opportunity to complete this investigation and train as a scientist. I appreciate the opportunity and 
know that through this experience I have developed into a better and more independent investigator.  
 I am grateful to my thesis committee for their direction and advice over the past few years, and for 
helping me achieve success in my project. Thank you to all the members of my committee, Dr. Darrell 
Yamashiro, Dr. Peter Canoll, Dr. Swarnali Acharyya, and Dr. Jason Wright. I have truly benefitted from all 
your knowledge, guidance, and support. Thank you, Dr. Yamashiro, for being my chair, and counseling me 
during my training. I am also grateful to Dr. Lora Hedrick-Ellenson for giving her time and effort to participate 
in my defense.  
I am indebted to Dr. Elham Azizi for working on this project with me by completing all of the RNA-
Seq data analysis in this work and for helping me to understand it. I really value all the time and effort she 
put into this project, and am grateful for many answered questions along the way. Her kindness and 
understanding was appreciated, and I could not have done this work without her.  
I would also like to thank Dr. Jill Slack-Davis for graciously providing us with the ID8 IP2 cell line 
with which I completed these experiments.  
I would like to recognize my colleagues from the Kitajewski laboratory for all their advice, 
assistance, and commiseration. I would like to acknowledge Dr. Naiche Adler for her mentorship and for 
advising me on writing this work. I would also like to give a special thank you to James Herts for 
communicating my data to me so I could finish writing this thesis while far away from the laboratory. Thank 
you to Valeria Borisenko for her kindness and support, and helping me start to learn mouse work.  
I appreciate both of my programs for allowing me to be a student at Columbia and complete my 
work. Thank you to the Columbia University MD/PhD Program, and the Integrated Program in Cellular 
Molecular and Biomedical Studies. A special thank you to Jeffrey Brandt and Zaia Sivo for their friendship 
and helping me along the way.  
I would like to acknowledge the financial support I have received from the National Institutes of 
Health National Cancer Institute award F31 CA19289.  
  
vii 
 I would also like to give a warm and special thanks to my first P.I. and still mentor Dr. Daphne Bell.  
She introduced me to my love and esteem of research and I would not have become a scientist without 
her. She is a wonderful mentor to me and has continued to advise me through my thesis journey even 
though I am no longer in her laboratory, and I will always be beholden to her. 
 Lastly, but most of all, I would like to thank my family, extended family, and friends. I could not have 
finished without them and their constant love and support. I owe them all for listening to me, and 
encouraging me to keep moving forward through this process. Their support is never ending and I 
appreciate all of them being there through my failures and accomplishments. I could not have survived 
without them.  I would like to thank Lisa, Amina, Rima, Rosa, and Steph for all their love. Thank you to 
Sonya. I would not have even attempted research, applied to this program, or believed I could do any of 
this without her. Thank you to my Dad for always being proud and supportive of me. And most importantly, 
thank you to my mother. Words cannot express my gratefulness for all the sacrifices she has made to get 
me to where I am today. She has been my comfort in difficult times, and her love, support, compassion, 







Ovarian Cancer  
 Ovarian cancer is the deadliest gynecologic malignancy. It is expected that in 2017 ovarian cancer 
will be the 5th leading cause of cancer death in women in the United States, with an estimated 22,400 new 
cases and 14,080 deaths in the current year (Siegel et al., 2017). Worldwide, ovarian cancer is the 8th 
leading cause of death in women, with an estimated 238,700 new cases and 151,900 deaths each year 
(Torre et al., 2015).  
The most common subtype of ovarian cancer is high grade serous ovarian cancer (HGSC), 
described in detail later in this introduction. Standard treatment for HGSC includes surgical cytoreduction 
(removal of macroscopic tumors) and combination chemotherapy with platinum (a DNA damaging agent) 
and taxane (a microtubule inhibitor) (Matulonis et al., 2016, Bowtell et al., 2015). HGSC recurs in over 80% 
of cases that were initially disseminated beyond the pelvis and 20-30% of HGSC cases will recur in less 
than 6 months (Matulonis et al., 2016, Berns and Bowtell, 2012). Recurrent tumors are also chemotherapy 
resistant in 80-90% of cases (Bowtell et al., 2015). Once disease recurs there is no standard therapy, 
although many other treatments and therapy combinations have been attempted (Matulonis et al., 2016). 
For example, chemotherapy drugs other than platinum and taxane agents, angiogenesis inhibitors, PARP 
inhibitors, and immunotherapy have been tested, but few treatments increase overall survival (Matulonis et 
al., 2016). Treatment is similar for other subtypes of ovarian cancer; however, other subtypes are more 
likely to be detected while still confined to the pelvis and treatments may include the use of other 
chemotherapeutics, or therapy based on tumor specific genetic alterations (Cont et al., 2015). Because of 
the potential for earlier stage of diagnosis, survival can be much higher for the other, less common, subtypes 
of epithelial ovarian cancer (Cont et al., 2015).  
Ovarian cancer is so deadly because it is often detected after metastasis throughout the 
peritoneum, and because it is likely to become resistant to chemotherapy and recur. Approximately 70-75% 
of cancers are discovered after dissemination of disease (Naora and Montell, 2005, Barbolina et al., 2009). 
Ovarian cancers are often initially diagnosed in late stages of development due to rapid dissemination of 
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tumors and the fact that most patients experience no symptoms, or non-specific symptoms such as fatigue 
and gastrointestinal discomfort (Matulonis et al., 2016). When detected at late stages, the 5-year survival 
rate is only 25%-30% (Matulonis et al., 2016, Cho and Shih Ie, 2009). 
 Unfortunately, early detection measures such as transvaginal ultrasound and screening for CA-
125, a tumor marker in blood serum, have not shown any effect on mortality rates (Matulonis et al., 2016, 
Cho and Shih Ie, 2009, Fathalla, 2013). It has been suggested that, because of the rapid dissemination 
exhibited by ovarian cancers, focus should be on detecting and treating low volume disease, when tumors 
are still less than 1cm and relatively sparse, and early detection of recurrence (Cho and Shih Ie, 2009, 
Kurman et al., 2008).     
HGSC metastasizes by forming direct extensions to adjacent organs and by transport of exfoliated 
cells in the peritoneal fluid to new sites on the peritoneal lining (Barbolina et al., 2009, Naora and Montell, 
2005). Non-adherent tumor cells are vulnerable to anoikis, or apoptosis triggered by detachment from 
extracellular matrix, but survive transport via supportive signals from the surrounding peritoneal fluid or by 
forming spheroids where adjacent cells can signal through adhesion molecules (Naora and Montell, 2005).  
Metastases form when tumor cells adhere to new sites on the peritoneal lining, which consists of a single 
layer of mesothelial cells over collagen-rich extracellular matrix and other stroma (Barbolina et al., 2009). 
Ovarian cancer is thought to preferentially attach to sites where the mesothelial layer is disrupted and 
extracellular matrix is exposed (Sodek et al., 2012). Once tumor cells adhere, they further reduce the 
integrity of the peritoneal mesothelial layer via interaction with the surrounding matrix and stroma that trigger 
mesothelial contraction, metalloprotease expression, and other signaling through cytokines and growth 
factors which leads to increased invasion, motility, and further growth of metastases (Barbolina et al., 2009, 
Rosen et al., 2009). 
Ovarian cancers often cause dramatic increases in the amount of peritoneal fluid, called ascites, 
which can result from tumor cell blockage of lymph nodes and/or an increase in vascular leakage in the 
tumors or adjacent tissues of the peritoneum (Naora and Montell, 2005, Barbolina et al., 2009). Ascites 
accumulation can increase the normal peritoneal fluid volume (less than 20mL) to volumes often over 
500mL, and can exceed 2L (Barbolina et al., 2009). Ascites accumulation is correlated with worse prognosis 
(Barbolina et al., 2009, Puls et al., 1996), possibly because ascites can contain many molecules that 
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support tumor growth and dissemination, including growth factors, extracellular matrix, proteolytic enzymes, 
and inflammatory signals (Barbolina et al., 2009).  
Most ovarian cancers are epithelial in origin (Matulonis et al., 2016). Non-epithelial ovarian cancers, 
which generally derive from germ cells or sex cord stromal cells, comprise about 10-15% of ovarian cancers 
and will not be discussed in detail here (Boussios et al., 2016).  
Epithelial ovarian cancer encompasses tumors from several tissues of origin with similar clinical 
presentation and reproductive tract derivation; it is a collection of diseases that are histologically and 
molecularly distinct, but share the ability to disseminate in the pelvis (Vaughan et al., 2011, Matulonis et al., 
2016). There are 4 histological subtypes of epithelial ovarian cancer: serous, endometrioid, clear cell, and 
mucinous (Berns and Bowtell, 2012, Cho and Shih Ie, 2009). Some of these are further categorized by high 
and low grade, describing the extent of differentiation (Cho and Shih Ie, 2009). Based on histological 
subtype and grade, epithelial ovarian tumors are separated into two groups, Types I and II (Shih Ie and 
Kurman, 2004). Type I and Type II tumors are molecularly distinct, showing activation or loss of different 
genes and pathways (Shih Ie and Kurman, 2004). For example, Type I tumors are more likely to have 
alterations in genes and pathways like KRAS, BRAF, and ARID1A, while Type II tumors are likely to have 
alterations in TP53, BRCA1/2, and CCNE1 (Nik et al., 2014, Berns and Bowtell, 2012). Type I tumors are 
low grade, have lower malignant potential, and are more likely to initially be platinum insensitive because 
their lack of alteration in DNA damage repair pathways; Type I tumors, however, respond better to treatment 
because these tumors are more likely to be detected at low stage, giving patients with these tumors higher 
survival rates (Bowtell, 2010, Cont et al., 2015). Type I tumors usually include low grade serous, low grade 
endometrioid, clear cell, and mucinous subtypes (Cho and Shih Ie, 2009, Nik et al., 2014). Type II tumors 
are more likely to be aggressive and arise rapidly (Bowtell, 2010, Cho and Shih Ie, 2009, Nik et al., 2014). 
Type II tumors are generally high grade serous, high grade endometrioid, clear cell, or undifferentiated/ 
mixed mesodermal tumors (Cho and Shih Ie, 2009). HGSC is the most common subtype, comprising ~75% 
of all ovarian cancers, and this subtype will be the focus of our experiments and discussion (Nik et al., 
2014).  
HGSC is characterized by a specific molecular signature. Almost all HGSC have TP53 loss or 
mutation and approximately half present with alterations in homologous recombination repair genes  
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(Bowtell et al., 2015, Cancer Genome Atlas Research, 2011, Ahmed et al., 2010). These alterations in 
tumor suppressors that affect DNA repair can lead to copy number changes in other genes that increase 
the progression of HGSC (Bowtell, 2010). Histologically, HGSC display atypical nuclei with high numbers 
of mitoses and papillary or solid growth with slit-like spaces (Cho and Shih Ie, 2009).  
Originally it was believed that all ovarian cancers derive from the ovarian surface epithelium (OSE), 
or ovarian cysts lined with OSE (Nik et al., 2014). However, it is currently believed that ovarian cancers can 
derive from several sources. For example, mucinous cancers are believed to originate from the 
gastrointestinal tract or endocervix, while endometrioid and clear cell tumors may derive from endometriosis 
(Wiegand et al., 2010, Fukunaga et al., 1997, Cho and Shih Ie, 2009, Tenti et al., 1992). The tissue of origin 
of HGSC is currently under debate, and HGSC has been suggested to derive from either the ovary, the 
fallopian tube/oviduct, or from endosalpingiosis, which is ectopic tissue outside the reproductive tract that 
resembles the fallopian epithelium (Nik et al., 2014). 
The historical assumption of an OSE origin of HGSC was based on observations such as 
correlation of incidence with ovulation, presence of tumors in the ovary, and presence of malignant tumors 
with benign ovarian cysts, indicating this may be their origin (Fathalla, 2013, Fathalla, 1971, Finn and Javert, 
1949, Dubeau, 2008, Dubeau and Drapkin, 2013). OSE cells express both epithelial and mesenchymal 
markers and characteristics, suggesting a level of plasticity amenable to the development of cancer (Naora 
and Montell, 2005, Barbolina et al., 2009). Ovulation and inflammation associated with ovulation are linked 
to development of ovarian cancer, indicating a critical role for the ovary; however, some data suggests that 
fallopian epithelium becomes trapped in the ovary and ovarian cysts during ovulation and later becomes 
tumorigenic in the inflammatory- and hormone-rich environment of the ovary (Rosen et al., 2009, Fathalla, 
2013, Dubeau and Drapkin, 2013). 
More recent data suggests a fallopian origin of HGSC. Tumors are thought to arise from fallopian 
secretory cells, which are unable to repair double strand breaks and thus are particularly susceptible to 
DNA damage and tumorigenic progression (Bowtell, 2010). Primary serous lesions (known as serous tubal 
intraepithelial carcinoma, or STIC) are often found in the fallopian epithelium, but not ovarian epithelium, of 
BRCA1/2 positive patients undergoing prophylactic removal of the ovaries and fallopian tube (salpingo-
oophorectomy), suggesting that fallopian lesions may be the primary origin of HGSC in some women (Piek 
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et al., 2001, Nik et al., 2014). Müllerian-specific Hox genes and Pax8 are expressed or overexpressed in 
some HGSC, suggesting genesis from Müllerian-derived tissue such as the fallopian tube and not the ovary 
(Cheng et al., 2005, Bowtell et al., 2015, Cheung et al., 2011, Laury et al., 2011). However, OSE may 
upregulate Müllerian markers during tumorigenic progression (Dubeau and Drapkin, 2013, Resta et al., 
1993). 
Contradicting both of these theories, some women who undergo prophylactic salpingo-
oophorectomy still develop HGSC, indicating that at least some HGSC originate from non-fallopian 
epithelium (Dubeau and Drapkin, 2013, Dubeau, 2008). This has led to yet a third hypothetical tissue of 
origin: endosalpingiosis, which is ectopic fallopian epithelium from developmental remnants or retrograde 
sloughing/menstruation (Kurman et al., 2011, Dubeau and Drapkin, 2013). Furthermore, some ovarian 
cancers are histologically mixed, and fallopian epithelium only gives rise to serous cancers (Dubeau and 
Drapkin, 2013). 
Given the substantial uncertainty in the literature, for the purposes of this thesis we will consider 
HGSC as one disease that may originate in any of these manners, but which are unified by their ability to 
develop disseminated disease with ascites accumulation, HGSC histology, and a HGSC molecular 
signature (Dubeau, 2008).  
The Notch signaling pathway 
The first known mutation of a Notch gene was discovered in Drosophila melanogaster almost a 
century ago and the gene was named for its resulting phenotype, abnormal notches in the border of the fly 
wing (Mohr, 1919). Since then, much has been discovered about the mechanisms of the Notch signaling 
pathway and the roles of Notch genes in directing development and disease progression. 
In mammals, Notch signaling occurs via four Notch genes, Notch1, Notch2, Notch3, and Notch4, 
which act as receptors, and five ligands Delta-like1 (Dll1), Dll3, Dll4, Jagged1, and Jagged2 (Borggrefe and 
Oswald, 2009, Hori et al., 2013, Radtke et al., 2005). The Notch genes and their ligands are single pass 
transmembrane proteins (Capaccione and Pine, 2013, Mumm and Kopan, 2000). The Notch proteins 
generally consist of an extracellular domain (N-terminus) containing a varying number of EGF-like repeats 
and an intracellular domain containing a RBPjκ association module (RAM) domain, two nuclear localization 
sequences (NLS), six Ankyrin repeats (ANK), a transactivation domain (TAD), and a proline, glutamate, 
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serine, threonine rich (PEST) domain at the C-terminus (Capaccione and Pine, 2013, Kopan and Ilagan, 
2009, Ehebauer et al., 2005). After translation, Notch is processed in the Golgi apparatus by a furin-
convertase cleavage at site 1 (S1) and the two peptides then form a heterodimer held together by a calcium-
coordinated non-covalent bond (Mumm and Kopan, 2000, Capaccione and Pine, 2013, Hori et al., 2013). 
Notch can be further processed by glycosylation, glucosylation, or fucosylation and shuttled to the cell 
membrane (Hori et al., 2013, Mumm and Kopan, 2000). Notch ligands also consist of an extracellular 
domain of EGF-like repeats and contain a DSL (Delta/Serrate/LAG-2) domain necessary for Notch 
interaction, but ligands have only a small intracellular domain with no TAD and do not undergo S1 cleavage 
(Kangsamaksin et al., 2015, Hori et al., 2013).  
Canonical Notch signaling activation requires direct contact between Notch and a ligand expressed 
in neighboring cells (Capaccione and Pine, 2013). Notch then undergoes a conformational change that 
allows for a second cleavage event at S2 by an ADAM/TACE (tumor necrosis factor α converting enzyme, 
part of the A Disintegrin And Metalloproteinase family) protein (Capaccione and Pine, 2013, Mumm and 
Kopan, 2000). This is immediately followed by cleavage at site S3 by a γ-secretase complex containing a 
presenilin catalytic domain (Capaccione and Pine, 2013, Mumm and Kopan, 2000, Bellavia et al., 2008, 
Borggrefe and Oswald, 2009). The S3 cleavage occurs at the intracellular border of the transmembrane 
domain and releases the Notch intracellular domain from the membrane, which then translocates to the 
nucleus to effect gene expression. Nuclear localized Notch intracellular domain binds the CSL (CBF-1/RBP-
Jκ, Suppressor of hairless, and Lag-1) transcriptional repressor complex and causes a conformational 
change that allows CSL to release its co-repressors, and instead bind Mastermind-like (MAML) and other 
co-activator proteins to form a transcriptional activator complex (Capaccione and Pine, 2013, Bellavia et 
al., 2008, Borggrefe and Oswald, 2009) (Figure 1.1). Thus, when freed from the membrane, the Notch 
intracellular domain converts repressor complexes to activator complexes and induces downstream target 
gene expression. Some well-established canonical targets induced directly by Notch signaling include HES 
(human hairy and enhancer of split) genes, HEY (hairy/enhancer of split related with YRPW motif) genes, 




Figure1.1 Canonical Notch receptor signaling leads to the activation of gene transcription.  
This figure illustrates the Notch signaling pathway. Notch goes through 3 cleavage events, the first to create 
a heterodimer which becomes localized to the cell membrane. Subsequent cleavage events are triggered 
by ligand binding, which causes a conformational change to expose the S2 cleavage site for ADAM/TACE. 
S3 cleavage is completed by γ-secretase, releasing the Notch intracellular domain to translocate to the 
nucleus. Once in the nucleus, the intracellular domain of Notch converts the CSL transcriptional repressor 




Notch signaling is modulated by multiple negative regulatory mechanisms. Notch signaling is 
downregulated by E3 ubiquitin ligases such as FBXW7 that direct Notch receptor degradation, endocytosis 
and endosomes that regulate Notch presence on the cell surface, and the C-terminal PEST domain that 
regulates protein stability and degradation (Mumm and Kopan, 2000, Bellavia et al., 2008, Hori et al., 2013). 
Notch interactions with ligands expressed on the same cell, rather than neighboring cells, often results in 
inhibition of Notch signaling (Hori et al., 2013). Canonical Notch pathway targets, such as NRARP, are 
involved in negative regulation of Notch signaling (Borggrefe and Oswald, 2009). Conversely, Notch 
signaling can be either enhanced or suppressed by addition of various post-translational side chains by the 
Fringe family and other glucosyltransferases (Kopan and Ilagan, 2009).  
Notch proteins can also engage in non-canonical signaling, which is independent of CSL complex 
activation or DSL domain containing ligands (Mumm and Kopan, 2000, Hori et al., 2013, Ayaz and Osborne, 
2014). Non-canonical signaling is not restricted to the nucleus, and often occurs in the cytoplasm; it can 
even occur in the mitochondrial or cell membrane (Andersen et al., 2012, Ayaz and Osborne, 2014). Notch 
can act through modulation of kinase signaling (Mumm and Kopan, 2000, Ayaz and Osborne, 2014). Notch 
has been shown to affect NF-κB, PI3K/AKT/mTOR, Wnt/β-catenin, and HIF1α signaling pathways 
independent of CSL in immune cells and particular cancers (Ayaz and Osborne, 2014, Andersen et al., 
2012).  
Notch genes were first identified as being critical in embryonic development, in particular for the 
differentiation of cell types. Notch signaling often determines the cell fate of adjacent cells, and is best 
known for its ability to mediate either lateral inhibition or lateral induction of cell types (Mumm and Kopan, 
2000, Hori et al., 2013, Borggrefe and Oswald, 2009). More recently, Notch signaling has been shown to 
be a causative or contributing factor for the development of many cancers. Notch receptors were first shown 
to be oncogenic in T-cell acute lymphoblastic leukemia (Capaccione and Pine, 2013). Since then, Notch 
and members of the Notch pathway have been shown to be oncogenic in acute myelogenous leukemia, 
non-small cell lung carcinoma, colorectal cancer, pancreatic cancer, melanoma, breast tumors, and others 
(Ntziachristos et al., 2014, Capaccione and Pine, 2013). Notch signaling can maintain cancer stem cells, 
induce proliferation, assist epithelial to mesenchymal transition, increase cancer cell motility, increase tumor 
angiogenesis, resist apoptosis and anoikis, and confer chemotherapy resistance (Capaccione and Pine, 
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2013, Takebe et al., 2014, Radtke and Raj, 2003, Ayaz and Osborne, 2014). Notch often works with other 
dysregulated pathways within the cell, such as RAS, to enhance tumorigenesis (Radtke and Raj, 2003). 
Conversely, Notch signaling has also been implicated as a tumor suppressive, particularly in certain 
squamous cell carcinomas where Notch is thought to drive terminal differentiation and therefore exit from 
the cell cycle (Nowell and Radtke, 2017, Ntziachristos et al., 2014, Radtke and Raj, 2003). Notch signaling 
can contribute to cancer development both through canonical and non-canonical signaling methods (Ayaz 
and Osborne, 2014).   
Our focus for this thesis will be on Notch3. Compared to Notch1 and Notch2, Notch3 has fewer 
EGF-like repeats in its extracellular domain (34 as opposed to 36) and a shortened C-terminal intracellular 
domain, which may result in differences in activation of downstream signaling (Lardelli et al., 1994, Bellavia 
et al., 2008). For example, the change in the TAD may lead to a preference for NOTCH3 to CSL binding 
sites near zinc finger promoters (Ong et al., 2006). Notch3 can undergo different conformational changes 
than other Notch receptors and also differentially recruits co-activators (Bellavia et al., 2008). Notch3 
appears to share many of the canonical transcriptional targets as other Notch genes, but shows different 
preferences for strongest induction (Beatus et al., 1999, Shimizu et al., 2002). For example, Hes1 is strongly 
upregulated by Notch1, but not Notch3 (Beatus et al., 1999, Beatus et al., 2001). Notch3 in particular has 
been implicated in cancers such as non-small cell lung carcinoma, breast cancer, T-cell leukemia, and 
ovarian cancer (Capaccione and Pine, 2013, Bellavia et al., 2008, Ayaz and Osborne, 2014, Ntziachristos 
et al., 2014). In cancer, it has also been shown that Notch3 has a preference for interaction with Jagged 
ligands (Bellavia et al., 2008, Choi et al., 2008, Chen et al., 2010, Steg et al., 2011, Hu et al., 2014).   
The role of Notch3 signaling in high grade serous ovarian cancer  
Ovarian cancer is correlated with high levels of Notch3 signaling in ovarian tumors, specifically in 
HGSC cases and derived cell lines. Unbiased screening of almost 500 HGSC tumors (Cancer Genome 
Atlas Research, 2011) demonstrated that the Notch3 pathway was altered in 22% of HGSC samples 
assessed. Most of these alterations are predicted to activate signaling, including copy number amplification, 
predicted activating mutations, and upregulation of mRNA expression compared to diploid tumors. The 
most frequent alterations of the Notch pathway were in NOTCH3 itself, but other parts of the Notch pathway 
were altered at lower frequency, including the JAGGED1 and JAGGED2 ligand genes and Notch activation 
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complex genes MAML1,MAML2, MAML3, and RBPJκ (CSL) (Cancer Genome Atlas Research, 2011). Re-
analysis of a modified version of the TCGA dataset including additional tumors showed that over half of 
HGSC samples also harbor deletions of WWP2, which targets NOTCH3 (but no other Notch genes) for 
endocytosis and degradation, and these WWP2 mutations correlate with increased Notch3 expression 
(Jung et al., 2014). 
Additional studies have confirmed that mutations predicted to increase Notch3 signaling occur at 
high frequency in serous ovarian cancers. NOTCH3 was found to have an increase in copy number in 
serous ovarian cancer in several independent studies, and the increased copy number correlated with 
higher levels of NOTCH3 protein (Lu et al., 2004, Nakayama et al., 2007, Park et al., 2006b, Shih Ie et al., 
2011). NOTCH3 transcripts were elevated in high grade serous cancers when compared with benign tumor 
levels, and NOTCH3 protein levels are upregulated in ovarian cancer patient samples (Jung et al., 2010, 
Liu et al., 2016, Park et al., 2010). Increases in NOTCH3 protein correlated with worse prognosis; patients 
with high levels of NOTCH3 showed shorter overall survival, higher grade and stage tumors, increased 
ascites accumulation, and increased recurrence (Jung et al., 2010, Liu et al., 2016, Park et al., 2010). 
Reanalysis of the original TCGA data determined that patients with NOTCH3 alterations demonstrated 
poorer overall survival as well (Hu et al., 2014).   
Jagged1 is the major Notch ligand found in HGSC. At the RNA level, Jagged1 is the most highly 
expressed Notch ligand in HGSC derived cell lines when compared to non-tumorigenic ovarian surface 
epithelial cell lines (Choi et al., 2008). NOTCH3 expressing tumors show high levels of JAGGED1 protein 
expression (Choi et al., 2008). JAGGED1 expression correlates with expression of NOTCH3 in HGSC, and 
endocytosis associated with Jagged1 can activate Notch3 signaling in an ovarian cancer cell line (Hu et al., 
2014). Notch3 can regulate Jagged1 expression and the receptor/ligand pair act in a positive regulatory 
loop in ovarian cancer cells (Chen et al., 2010). JAGGED1 is also expressed in cells in the peritoneal 
environment, suggesting that it may participate in tumor-peritoneal interactions (Choi et al., 2008, Steg et 
al., 2011). 
Notch3 levels also correlate with tumorigenic phenotypes in ovarian cancer cell lines. Proliferation, 
viability, cell cycle arrest, and apoptosis have all been linked to Notch3 activity in ovarian cancer, indicating 
a role for Notch3 in tumor growth (Hu et al., 2014, Park et al., 2006b, Zhang et al., 2012, Zhang et al., 
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2015). Notch3 inhibition reduced proliferation and induced apoptosis, indicating that Notch3 is a critical cell 
survival factor in some ovarian cancers. Notch3 signaling also upregulates other tumorigenic behaviors, 
such as epithelial to mesenchymal cell transition and resistance to anoikis (Gupta et al., 2013, Hu et al., 
2014, Brown et al., 2015). 
Lastly, Notch3 has a role in both platinum and taxane chemotherapy resistance. Patient samples 
with elevated Notch3 transcripts or protein are significantly more likely to become resistant or refractory to 
chemotherapy (Park et al., 2010, Rahman et al., 2012, Jung et al., 2010). In vitro, high levels of NOTCH3 
have been correlated with increased ovarian cancer cell viability in the presence of platinum chemotherapy, 
and Notch inhibition during platinum treatment has been shown to reduce viability and increase apoptosis 
(Park et al., 2010, Rahman et al., 2012, Gupta et al., 2013, McAuliffe et al., 2012). NOTCH3 expressing 
ovarian cancer lines implanted into mouse hosts respond to combination platinum chemotherapy and Notch 
inhibition better than platinum therapy alone (Hu et al., 2014, McAuliffe et al., 2012, Shah et al., 2013). 
Combination therapy using taxane and several different methods of Notch3 inhibition has also proven 
effective at reducing tumor burden or cell viability (Groeneweg et al., 2014a, Hu et al., 2014, Kang et al., 
2015, Jeong et al., 2017). 
It is not currently known whether the mechanisms of increased growth, viability, anoikis resistance, 
and chemotherapy resistance are related to canonical, non-canonical, or both types of Notch3 signaling. 
There is some evidence that Notch3 may act in a non-canonical pathway through Wnt/βcatenin signaling 
in ovarian cancer (Chen et al., 2010) or other pathways (Ayaz and Osborne, 2014).  
Previous studies thus implicate Notch3 signaling as critical in ovarian cancer development and 
progression. However, the mechanism by which Notch3 signaling affects metastasis and cancer 
development remains to be elucidated. Analysis of Notch3 pathway activation and its effects in an ovarian 
cancer model will provide insights into the causal relationship of Notch3 and ovarian tumorigenesis, the 
downstream targets that drive the greater lethality of Notch3 expressing tumors, and the mechanisms of 






MATERIALS AND METHODS 
 
Cell culture  
The Peo1 human ovarian cancer cell line was obtained from Dr. Andrea Califano’s laboratory at 
Columbia University. Cells were cultured in RPMI with 10% FBS, 2mM sodium pyruvate, and 1% penicillin-
streptomycin. This line was then lentivirally infected with a reporter via a FUW vector with firefly luciferase, 
mCherry, and puromycin resistance genes.    
The OVCAR5 human ovarian cancer cell line was acquired from the Dr. Tian-Li Wang laboratory 
at Johns-Hopkins University and were cultured in RPMI with 10% FBS and 1% penicillin-streptomycin. 
OVCAR5 was lentivirally infected with virus generated from a FUW plasmid containing firefly luciferase, 
mCherry, and puromycin resistance to follow tumors in vivo.    
The ID8 line, along with ID8 luciferase and ID8 GFP, were obtained from the Dr. Katherine Roby 
laboratory at the University of Kansas Medical Center. Cells were cultured in DMEM 10% fetal bovine serum 
(FBS) 1% insulin, transferrin, sodium selenite (Sigma I1884), and 1% penicillin-streptomycin. 
The ID8 IP2 line was from our collaborators in the Dr. Jill Slack-Davis laboratory at University of 
Virginia. The ID8 IP2 cell line was lentivirally infected with a FUW firefly luciferase and mCherry construct. 
The ID8 IP2 luciferase cell line was lentivirally infected with Notch3 intracellular domain (pCCL Notch3 
intracellular domain-HA IRES-GFP, Notch3IC) or control vector (pCCL multiple cloning site only, Control). 
ID8 IP2 lines were cultured in DMEM 10% FBS 1% insulin, transferrin, sodium selenite (Sigma-Aldrich 
I3146), and 1% penicillin-streptomycin. 5 total sets of lentivirally infected ID8 IP2 luc Notch3IC activated 
and control line biological replicates were generated. 
Ovarian cancer lines OVCAR3, A2780, and SKOV3-IP1 were obtained from the Dr. Joanna 
Burdette laboratory at University of Illinois at Chicago (originally from ATCC), the Dr. Tian-Li Wang 
laboratory at Johns-Hopkins University, and the Dr. Olga Razorenova laboratory at University of California, 
Irvine respectively. Lines were cultured in RPMI 1640 10% FBS 1% penicillin-streptomycin.  
All cultured cells were incubated at 37°C in 5% CO2.  
Peo1 luciferase modeling in vivo 
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 Peo1 luciferase ovarian cancer cells were injected intraperitoneally in female NCR nu/nu athymic 
mice. A total of 5 mice were injected with 1.0x107 cells in phosphate buffered saline each. Mice were 
between 5-7 weeks old at the time of injection. Mice were evaluated weekly for mass, circumference, and 
by bioluminescent imaging. Mice were injected with 100μL of 30mg/mL luciferin (XenoLight D-Luciferin, 
Perkin Elmer) intraperitoneally, anesthetized with isoflurane, and imaged at 10 minutes post injection with 
the IVIS Spectrum in vivo imaging system (Perkin Elmer). Mice were also dissected at endpoint to visually 
assess for the presence or lack of tumors. The Columbia University Institutional Animal Care and Use 
Committee approved all animal experiments.  
OVCAR5 luciferase modeling in vivo 
 OVCAR5 luciferase were injected intraperitoneally in 10-week-old female NCR nu/nu athymic mice. 
5 mice were each injected with 2.5x106 cells in sterile phosphate buffered saline. Mice were evaluated 
weekly for mass, circumference, and by bioluminescent imaging. Mice were injected with 100μL of 
30mg/mL luciferin (XenoLight D-Luciferin, Perkin Elmer) intraperitoneally, anesthetized with isoflurane, and 
imaged at 10 minutes post injection with the IVIS Spectrum in vivo imaging system (Perkin Elmer). Mice 
were also dissected at endpoint to visually assess for the presence or lack of tumors. The Columbia 
University Institutional Animal Care and Use Committee approved all animal experiments.      
ID8 luciferase modeling in vivo 
 ID8 luciferase were injected either intraperitoneally or subcutaneously into 5- to 7-week-old female 
NCR nu/nu mice. Each injection consisted of 5x106 cells in phosphate buffered saline. Intraperitoneally 
injected mice were evaluated weekly for mass and by bioluminescent imaging. Subcutaneously injected 
mice were evaluated weekly by mass, caliper measurements of tumors, and bioluminescent imaging. 
Bioluminescent imaging of mice was performed by intraperitoneal injection with 100μL of 30mg/mL luciferin 
(XenoLight D-Luciferin, Perkin Elmer), anesthetization with isoflurane, and imaging at 10 minutes post 
injection with the IVIS Spectrum in vivo imaging system (Perkin Elmer). Mice were also dissected at 
endpoint to visually assess for the presence or lack of tumors. For intraperitoneal injected mice, we also 
collected peritoneal wall and intestinal tissue with tumors to evaluate histology.  
A second experiment with the ID8 luciferase cell line was completed by intraperitoneally injecting 
a second cohort of 4 NCR nu/nu mice and a cohort of 4 C57BL/6 mice. Mice were injected with 4x106 cells 
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in phosphate buffered saline per mouse. All mice were between 5-7 weeks of age at the time of injection. 
Mice were assessed weekly for mass and by bioluminescent imaging. Imaging was completed with the 
same protocol as the previous ID8 luciferase experiment. C57BL/6 mice only were either shaved or fur was 
removed by depilatory cream on the abdomen prior to imaging. C57BL/6 mice were sacrificed at day 43 
due to lack of bioluminescent signal, and mice were dissected and visually assessed for presence of tumor 
burden. NCR nu/nu mice were sacrificed between days 98 and 111.    
The Columbia University Institutional Animal Care and Use Committee approved all animal 
experiments.  
ID8 IP2 luciferase modeling in vivo 
 ID8 IP2 luciferase cells were injected intraperitoneally into either NCR nu/nu or C57BL/6 mice. All 
mice were injected with 2x106 cells in phosphate buffered saline. C57BL/6 mice were injected at 13-16 
weeks of age and sacrificed in the 9th week post tumor injection on day 65. NCR nu/nu mice were injected 
at 16-18 weeks of age and were sacrifice in the 7th week post injection of tumor cells at day 46. Mass and 
bioluminescent imaging of tumor burden was assessed weekly. At endpoint, mice were dissected and 
bioluminescent imaging of the peritoneal wall tumor burden was assessed as well. Live bioluminescent 
imaging of mice was performed by intraperitoneal injection with 100μL of 30mg/mL luciferin (XenoLight D-
Luciferin, Perkin Elmer), anesthetization with isoflurane, and imaging at 10 minutes post injection with the 
IVIS Spectrum in vivo imaging system (Perkin Elmer). Fur from the abdomen of C57BL/6 mice was either 
shaved or removed by depilatory cream prior to live imaging. Imaging at time of sacrifice was accomplished 
by addition of 100 μL of 30mg/mL luciferin mixed with 400 μL of phosphate buffered saline directly to the 
peritoneal wall and diaphragm tissue. Measurements were captured at 5 min post addition of luciferin. 
Dissected tissue from nude mice was also sectioned and assessed for histology.  
 A second cohort of C57BL/6 female mice was injected at 7 weeks of age with 2x106 ID8 IP2 
luciferase cells in phosphate buffered saline. Mice were sacrificed at either 10 or 15 weeks post injection. 
In addition to measures completed on previously assessed ID8 IP2 luciferase injected mice, these mice 
were also weekly evaluated for circumference, and the volume of ascites was measured at the time of 
sacrifice.    
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The Columbia University Institutional Animal Care and Use Committee approved all animal 
experiments. 
ID8 IP3 luciferase modeling in vivo 
 ID8 IP3 tumors were generated by collecting peritoneal wall with tumors and ascites containing 
tumors from C57BL/6 mouse #10 of the second cohort of C57BL/6 mice injected with 2x106 ID8 IP2 
luciferase cells. This mouse was chosen for tumor harvest based on the high presence of luminescent 
signal at the time of sacrifice compared to similar treated mice. The peritoneal wall tissue was enzymatically 
digested with collagenase IV, hyaluronidase V, and DNase I at 37°C. Red blood cells were then lysed, and 
cells were collected by centrifugation and passage through a 70 μm cell strainer. Ascites was subjected to 
red blood cell lysis and cells were collected in the same manner. Resulting cells were subjected to 
fluorescent activated cell sorting (FACS) for mCherry, which should be present in the tumor cells based on 
the FUW luciferase mCherry puromycin resistance construct lentivirally infected into the ID8 IP2 luc cell 
line that generated the tumors. FACS cells were then cultured in vitro under puromycin selection, which 
should select for cells with the firefly luciferase reporter. Cells were assessed in vitro for mCherry expression 
via fluorescent microscopy, and with reagents from the Promega Dual-Luciferase® Reporter Assay System 
for positive luciferase presence to confirm reporter activity in cells before injection.    
 C57BL/6 mice were injected intraperitoneally with 2x106 ID8 IP3 cells either from peritoneal tumor 
cells, or ascites tumor cells in phosphate buffered saline. 4 mice were injected with each line for a total of 
8 mice. Mice were assessed weekly for mass, circumference, and by bioluminescent imaging for the first 9 
weeks post tumor injection. Imaging was performed by intraperitoneal injection of mice with 100μL of 
30mg/mL luciferin (XenoLight D-Luciferin, Perkin Elmer), anesthetization with isoflurane, imaging at 10 
minutes post injection with the IVIS Spectrum in vivo imaging system (Perkin Elmer). Abdominal fur of mice 
was removed via shaving or depilatory cream prior to imaging. Mice were sacrificed between 10 and 17 
weeks post injection based on visible ascites accumulation and signs of illness. Mice that did not 
accumulate ascites were sacrificed at 17 weeks. At the time of sacrifice mice were dissected and assessed 
visually for the presence or absence of tumors.   





Tissue from mice was collected at time of dissection and was snap frozen in optimal cutting tissue 
compound (Tissue-Tek® O.C.T.). Samples were then sectioned at 5 μm and mounted on slides.   
Hematoxylin and eosin (H&E) staining was performed on frozen sections. Permount mounting media was 
added to slides and sections were covered with glass coverslips.  
Immunofluorescent staining for vasculature of ID8 luciferase tumors was completed with antibody 
to CD31 (rat anti mouse CD31, BD Biosciences 553370) at 1:100 in blocking buffer, followed by secondary 
antibody donkey anti rat 594 (Donkey anti-Rat IgG Highly Cross-Adsorbed Secondary Antibody Alexa Fluor 
594, ThermoFisher A-21209) at 1:1000. Vasculature stain on frozen sections of ID8 IP2 luciferase tumor 
sections was completed with a rat anti endomucin primary antibody (Endomucin Antibody V.7C7 IgG2a, 
Santa Cruz sc-65495) diluted to 1:500 in blocking buffer. The same secondary antibody, donkey anti rat 
594 at a 1:000 dilution, was used. Vectashield mounting medium with DAPI (H-1200, Vector Laboratories) 
was added to stained sections and covered in glass coverslips.  
Images were acquired on a Nikon Eclipse E800 Fluorescence Microscope with Nikon High-
Resolution Digital Camera DXM 1200. Images were taken in Microsoft Image Pro Plus Morphometric 
Software 4.5. Photos were then modified in ImageJ (NIH) (Schneider et al., 2012).    
Lentiviral infection 
 Lentiviral infection was completed by first transfecting 293T packaging cells with virus components, 
and then using produced virus to infect target cancer cells. Calcium phosphate transfection was completed 
by adding 3μg of envelope plasmid pVSVG, 5μg of packaging plasmid pRRE, 2.5μg of splicing regulator 
pRSV-Rev, and pCCL empty vector or vector with the gene of interest (FUW mCherry luciferase, pCCL HA 
tagged Notch3 intracellular domain, or pCCL GFP) to 2.5M CaCl2 and 2X HBS. Transfected cells were 
allowed to sit overnight at 37°C in 5% CO2, and then the media was changed to the media preferred by the 
target cancer cell. This conditioned media was collected from transfected 293T cells and 0.45μm filtered to 
collect virus while removing other unwanted components such as contaminating 293T cells. Virus was then 
added to target cancer cells overnight at 37°C in 5% CO2. Target cells were infected twice and then 
switched to complete target cell media without virus. Target cells were fluorescently imaged to confirm 
  
17 
successful infection, and lysates were subjected to western blot to confirm protein production for the gene 
of interest (see immunoblotting).  
Retroviral infection 
 Retroviral infection was completed by first transfecting GP2-293 packaging cells with viral 
components, and then using produced virus to infect target cancer cells. Calcium phosphate transfection 
of GP2-293 was conducted with 10μg of envelope plasmid pVSVG and 10μg of pQCXIN vector either alone 
or with the gene of interest (full length Notch3 tagged with HA, or EGFP) with 2.5M CaCl2 and 2XHBS for 
6 hours. 293T were then cultured overnight in target medium at 37°C in 5% CO2. To infect cells, media from 
GP2-293 was removed and 0.45μm filtered to collect virus, and was subsequently added to target cells with 
8μg/mL of polybrene overnight at 37°C in 5% CO2. Infection was completed twice on cells. Cells were then 
selected with G418 (Sigma G8168-10ML). 
Immunoblotting 
Western blot was performed on 15μg of cell lysates subjected to SDS-PAGE electrophoresis. 
Lysates were run in an 8% gel and subsequently blotted to nitrocellulose membrane. Notch3 antibody 
(Santa Cruz Biotechnology Inc., sc-5593) according to the manufacturer is a rabbit polyclonal antibody 
targeted to amino acids 2107-2240 of mouse Notch 3. α-Tubulin antibody (Sigma-Aldrich, T6074) is a 
mouse monoclonal antibody. HA tag antibody (Cell Signaling Technology C29F4) is a rabbit monoclonal 
antibody. Secondary IgG horseradish peroxidase conjugated antibodies include goat anti-rabbit (Sigma-
Aldrich, A6154), and sheep anti-mouse (GE Healthcare Life Sciences, NA931VS). Enhanced 
chemiluminescence was used to detect secondary antibodies (Thermo Scientific™, SuperSignal™ West 
Femto Chemiluminescent Substrate, or GE Healthcare Life Sciences, Amersham ECL).  
Semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) 
RNA was extracted using the RNeasy Mini Kit (QIAGEN, 74104), and cDNA was generated using 
Verso™ cDNA synthesis Kit (Thermo Scientific™, AB1453A). 1 unit of Maxima Hot Start Taq polymerase 
(ThermoFisher Scientific) was added per reaction to a final concentration of 1X PCR buffer, 1.5mM MgCl2, 
0.2mM dNTPs, and 0.2 µM of each primer for each gene were mixed in molecular grade water. 150ng of 
cDNA template was added to each reaction. Thermal cycler cycle conditions were as follows: 94°C 4min, 
35 cycles of 94°C 45sec, 60°C 1min, 72°C 1min, and 72°C 5min followed by 4C. Primer sequences are 
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listed in the appendix. (Specifications for Platinum Taq (ThermoFisher Scientific) were used, but Maxima 
Hot Start Taq was substituted.)  
Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)  
RNA was extracted using the RNeasy Mini Kit (QIAGEN, 74104), and cDNA was generated using 
Verso™ cDNA synthesis Kit (Thermo Scientific™, AB1453A). Relative mRNA expression was determined 
by assessing generated cDNA for Notch3, Hes1, Hey1 and HeyL on a Life Technologies ABI ViiA7TM Real-
Time PCR system using ABsolute Blue qPCR SYBR Green ROX (Thermo Scientific™, AB4163A) reagent. 
All 5 lentiviral infected sets of ID8 IP2 luc lines was assessed. Mean threshold cycle numbers (Ct) were 
determined for each gene and compared to the mean Ct of beta actin. The fold change compared to control 
was calculated according to the formula 2(- Δ ΔCt) comparing the Notch3IC and Control Ct normalized to beta 
actin Ct. Results were graphed in GraphPad Prism 7 software. Primer sequences are listed in the appendix.  
Proliferation 
Proliferation/ viability assays were performed by seeding 2500 cells per well in a 24 well plate and 
assessing the number of viable cells at 48 hours with WST-8 (Dojindo Molecular Technologies) absorbance 
readings at 450nm. 450nm readings were compared to readings of a standard curve generated from like 
cells. 5 separate experiments were performed with 3 replicates of both Notch3IC and Control. One matched 
set of lentiviral infected ID8 IP2 luc was assessed (Set #1). Graphs and statistical analysis were generated 
in GraphPad Prism 7.   
 Experiments with FACS Notch3IC and Control, were completed with the same procedure. All data 
points from two experiments of sextuplicate plates were analyzed.  
Colony formation in soft agar  
Colony-forming plates were prepared by layering 0.75% agar in media, 0.75% agar and 2x104 cells, 
0.75% agar in media, and complete media in a 24 well plate in the listed order (see cell culture). Cells were 
incubated at 37°C in 5% CO2 for 3 weeks, changing media layer every other day. At 3 weeks, plates were 
stained with MTT at 37°C in 5% CO2 for 3 hours followed by washing with phosphate-buffered saline. Five 
5X photos per well were taken and the number of colonies and area of colonies were evaluated with ImageJ 
(NIH) software (Schneider et al., 2012). 4-6 wells were evaluated for each of 3 experiments conducted on 
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one matched ID8 IP2 luciferase line set (Set #1). Graphs and statistics were generated with GraphPad 
Prism 7.  
Cisplatinum therapy dose response 
ID8 IP2 luciferase Notch3IC and Control lines were seeded at 2000 cells per well in a 96 well plate 
and were left to attach overnight at 37°C and 5% CO2. Cells were subsequently subjected to cisplatinum 
doses of 0μM (DMSO vehicle alone at 16μM), 2μM, 4μM, 8μM, or 16μM for 48 hours at 37°C and 5% CO2. 
Cisplatinum was obtained from Sigma-Aldrich (P4394-100MG), and dissolved in DMSO at 10mM 
concentration. Cisplatinum was then diluted to 1mM in complete media (see cell culture), prior to each 
experiment before making dilutions for cell treatment. After 48 hours, cells were treated at a final 
concentration of 10μg/mL fluorescein diacetate (FDA) and 0.1% eosin Y in complete media for 20min at 
room temperature in the dark. The FDA fluorescently stains viable cells by being converted to fluorescein 
by cellular esterases, while the eosin Y quenches fluorescence in cells that are not viable (Keshelava et 
al., 2005). Cells were then assessed on the DIMSCAN, an imager that measures fluorescence staining live 
cells. 4 separate experiments were completed on ID8 IP2 luc Notch3IC and Control from Set #1.  
ID8 IP2 luciferase Notch3IC and Control in vivo model  
In vivo implants in NCR-nu/nu athymic mice were performed via intraperitoneal injection with 2x106 
ID8 IP2 luciferase Notch3IC or Control tumor cells in phosphate buffered saline. Implants were performed 
in 6 to 8-week-old female mice. A total of 76 mice were injected, and the 69 which developed tumor burden 
were assessed. Mice were assessed weekly via circumference measurement and IVIS Spectrum In Vivo 
Imaging System (PerkinElmer) bioluminescent imaging. Mice were dissected and IVIS imaged at the time 
of sacrifice for peritoneal wall and ovary tumor burden. Mice were sacrificed according to 25% or greater 
increase in circumference, or due to cachexia criteria of body condition score BC1 or BC2. For one 
experiment, mice were all sacrificed at 8 weeks. For this 8-week experiment, Set #2 of ID8 IP2 luc lines 
was used (9 Control, 10 Notch3IC). All remaining mice were injected with cells from the lentiviral infection 
for Set #1. The Columbia University Institutional Animal Care and Use Committee approved all animal 




RNA was extracted using the RNeasy Mini Kit (QIAGEN, 74104) and the RNase-Free DNase Set 
(QIAGEN, 79254). RNA samples from 4 separate lentiviral infected ID8 IP2 luciferase line pairs (Sets #1 - 
#4, Control and Notch3IC) were assessed. RNA-Seq data was generated by the JP Sulzberger Columbia 
Genome Center. Poly-A pull down was used to enrich for mRNA. An Illumina TruSeq RNA Prep Kit was 
used to prepare libraries. Briefly, library preparation for RNA-Seq entails fragmenting the RNA, strand 
synthesis with random primers, end repair and addition of adapter sequences that interact with the 
sequencing platform, and lastly purification and amplification of products. 25 to 30 million 100 base pair 
single end raw passing filters reads were then sequenced on an Illumina HiSeq 2000 or 2500 instrument. 
Sequence generated by Illumina software was format converted using bcl2fastq software. TopHat software 
was used to match generated sequence reads to the murine genome. Cufflinks software was used to 
determine the number of sequence read counts for each gene. DESeq analysis of gene counts to evaluate 
differential gene expression was performed followed by selection of genes with adjusted p-value < 0.1 and 
a 1 Log2 fold change in expression. The narrowed list of genes was subjected to pathway analysis using 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 
6.7 analysis wizard (NIAID, NIH). Pathway analysis was also assessed using the Broad Institute’s Gene 
Set Enrichment Analysis (GSEA) after mouse genes were converted to human orthologs using 
HomoloGene build 68 (NCBI, NIH). DESeq assessment confirmation and all pathway analysis was 
completed by Dr. Elham Azizi in the laboratory of Dr. Dana Pe’er (Columbia University/ Memorial Sloan 
Kettering Cancer Center).  
Flow cytometry of Itga1 
Flow cytometry was completed on 3 separate lentivirally infected line sets over 2 experiments. ID8 
IP2 luc lentiviral Sets #3, #4, and #5 were used. 5x106 were stained in 100µL of flow cytometry buffer 
consisting of 1X phosphate buffered saline with 0.1%NaN3 and 0.5% bovine serum albumin. Cells were 
stained with 0.2μg of either hamster anti-rat/mouse CD49a or isotype control conjugated to Alexa Flour 647 
(BD Pharmingen™ 562113, and 562112). All washes were completed in 500µL of flow cytometry buffer 
described above. After staining, cells were fixed in flow cytometry buffer with 1% paraformaldehyde, and 
filtered through a cell strainer cap with 35µm nylon mesh. A GalliosTM flow cytometer (Beckman Coulter) 
instrument was used to evaluate samples, and analysis was completed with FlowJo version 10.2 software. 
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Graphs were generated of all the data points for the two experiments, and for the average of each line set 
for the 2 experiments (log10 transformed data). Graphs and statistics were generated in GraphPad Prism 
7.  
Flow cytometry of Itga11 
Flow cytometry was completed on 3 separate lentivirally infected line sets over 2 experiments. Sets 
#3, #4, and #5 were used. 5x106 were stained in 100µL (for primary) or 200µL (for secondary) of flow 
cytometry buffer consisting of 1X phosphate buffered saline with 0.1%NaN3 and 0.5% bovine serum 
albumin. Cells were stained with 1.0μg of either rabbit anti-human/mouse/rat ITGA11 (Biorbyt, orb184286) 
or rabbit IgG isotype control (ThermoFisher Scientific 02-6102) primary antibody. Cells were subsequently 
washed and then stained with 0.4μg of secondary donkey anti-rabbit IgG Alexa Flour 647 (ThermoFisher 
Scientific A-31573). All washes were completed in 500µL of flow cytometry buffer described above. After 
staining, cells were fixed in flow cytometry buffer with 1% paraformaldehyde, and filtered through a cell 
strainer cap with 35µm nylon mesh. A GalliosTM flow cytometer (Beckman Coulter) instrument was used 
to evaluate samples, and analysis was completed with FlowJo version 10.2.  
Adhesion to extracellular matrix (ECM)  
24 well plates were coated with extracellular matrix and then blocked with 1% bovine serum 
albumin. Cells were seeded and incubated at 37°C in 5% CO2 for 30 to 90 minutes. Medium was removed 
and non-adherent cells were washed away with phosphate-buffered saline. Adherent cells were fixed with 
methanol and stained with 0.1% crystal violet. Cell counts for each well were generated with a Celígo 
instrument and software (Nexcelom Bioscience). The Celígo is an image cytometer which has the ability to 
scan plates and take brightfield or fluorescent cell images. Brightfield images were taken of the entire well 
and assessed by direct cell counting. The following extracellular matrices were assessed: collagen I 
(Corning™ 354236), collagen IV (Corning™ 354233), fibronectin (Corning™ 354008), laminin (Corning™ 
354232), and vitronectin (R&D Systems 2349VN100). Three separate lentivirally infected sets of ID8 IP2 
luc Notch3IC and Control matched lines were assessed in triplicate on 3 separate occasions (Sets #3 - #5). 
Means were calculated and the Notch3IC mean was compared to Control for each line. Graphs and 
corresponding statistics were generated in GraphPad Prism 7.  
Adhesion to Collagens with Antibody Blocking of Itga1  
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96 well plates were coated with rat tail collagen I (Corning™ 354236) or mouse collagen IV 
(Corning™ 354233) and then blocked with 1% bovine serum albumin. Cells were incubated with 10μg/mL 
of either Itga1 inhibitory antibody (BD Biosciences, 555000) or isotype control (BD Biosciences, 553961) 
rotating (ThermoFisher Scientific HulaMixerâ) at 37°C in 5% CO2 for 30min. Bovine serum albumin was 
removed from wells, and cells were then seeded on collagens. Cells were allowed to adhere at 37°C in 5% 
CO2 for 120 minutes. Medium was removed and non-adherent cells were washed away with phosphate-
buffered saline. Adherent cells were fixed with methanol and stained with 0.1% crystal violet. Cell counts 
for each well were generated with a Celígo cytometer instrument and software (Nexcelom Bioscience). 
Brightfield images were obtained and cells were assessed by direct cell counting. Three separate lentivirally 
infected sets of ID8 IP2 luc Notch3IC and Control matched line biological replicates were assessed in 
triplicate (Sets #3 - #5). Means were calculated and the Notch3IC mean was compared to Control for each 
line. Graphs and corresponding statistics were generated in GraphPad Prism 7.  
Migration without extracellular matrix 
The migration scratch/wounding assay was performed by scraping a confluent monolayer of cells 
in a 12-well plate with a p200 tip and allowing the cells to close the gap over the course of 12 hours. 
Experiments were repeated in triplicate 3 times for 3 separate ID8 IP2 luciferase lentiviral infected line sets 
(Sets #1, #2, #4). Photos were taken every 3 hours for 12 hours at 10x. Images were adjusted to crop areas 
outside the microscope camera field, and images were processed with “find edges” and “sharpen” tools to 
increase contrast between the scratch and cellular areas in ImageJ (NIH) (Schneider et al., 2012). Images 
were quantified with TScratch (Tobias Gebäck and Martin Schulz, ETH Zürich). Graphs and statistical 
analysis were generated in GraphPad Prism 7.   
Migration over extracellular matrix 
Migration experiments were completed in OrisTM cell migration assay collagen I or fibronectin 
coated 96 well plates (Platypus Technologies, CMACC1.101 or CMAFN1.101). This assay comes as a 96 
well plate pre-coated with extracellular matrix and prepared with a stopper/plug in the center of each well. 
Cells were seeded in the plate around the stopper and incubated at 37°C and 5%CO2 overnight to create 
a confluent monolayer around the plug. Once plugs were removed, cells were imaged at 0, 6, 12, and 24 
hours. Cells were evaluated and analyzed with a Celígo cytometer instrument and software (Nexcelom 
  
23 
Biosciences). Brightfield images were obtained and confluence was assessed for the cellular area. 3 
matched sets of lentivirally infected ID8 IP2 luciferase lines were assessed in quadruplicate twice (Sets #3 
- #5). Graphs display the average of the 2 experiments for each line set. Graphs and statistics were 
generated with GraphPad Prism 7.  
Invasion through Matrigel GFR 
Invasion assays were performed in triplicate in BioCoat™ 24 well transwell inserts with 8μm pores 
pre-coated with Growth Factor Reduced Matrigel (Corning, 354483). A total of 3 experiments were 
performed with one ID8 IP2 luciferase line set (Set #1). After serum starving cells for a minimum of 16 
hours, 1x104 cells were seeded in serum free media (1% penicillin/streptomycin) in the Matrigel coated 
inserts. Media with 10% FBS and 1% insulin, transferrin, sodium selenite was plated below the insert. Cells 
were incubated for 24 hours at 37°C in 5% CO2, and were then fixed with methanol and stained with 0.1% 
crystal violet. 4 20x photos per insert were taken and quantified by counting individual cells in ImageJ (NIH) 
(Schneider et al., 2012). Data for each 20x field was plotted in GraphPad Prism 7. Data for non-coated 
transwell inserts without ECM were also collected and analyzed in conjunction with each BioCoat 
experiment. 
Invasion through collagen I  
Invasion experiments through collagen I were completed using the CytoSelect™ 24-Well Cell Invasion 
Assay Collagen I, Colorimetric Format (Cell Biolabs, Inc., CBA-110-COL). 3 separate sets of ID8 IP2 
luciferase lines were assed in triplicate (Sets #3 - #5). After serum starvation for a minimum of 16 hours, 
2.5x105 cells were seeded per insert in serum free medium, and media with 10% FBS and 1% insulin, 
transferrin, sodium selenite was added in the well below the insert. Cells were allowed to invade for 72 
hours. Cells were stained, and the stain was extracted according to manufacturer protocol. Samples were 







MOUSE MODELING OF OVARIAN CANCER TO BEST REPLICATE 




In order to study the role of Notch3 signaling in ovarian cancer, we chose an appropriate animal 
model that would closely resemble patient disease for high grade serous ovarian cancer (HGSC), the most 
common and deadly histologic subtype of ovarian cancers (Chapter 1). Our goal was to identify a model 
that would appropriately replicate the peritoneal metastasis characteristic of HGSC as well as display 
similarity to the histology and environment of HGSC. HGSC presents with metastatic ovarian cancer lesions 
that seed on the human peritoneal wall and organs as shown in Figure 3.1, and we endeavored to replicate 
this disease state. In addition to determining if a model was appropriate to replicate HGSC, we sought to 
determine appropriate methods to characterize and measure disease burden in order to quantify disease 
progression.    
There exist a large number of mouse and other animal models for ovarian cancer which each have 
advantages and drawbacks. In addition, the tissue of origin of ovarian cancer is currently being debated, 
and new models posit that ovarian cancer may derive from a variety of tissue sources (Chapter 1). Ovarian 
cancer may originate either from the ovary or the oviduct/ fallopian tube, and there is evidence to support 
both origins (see Chapter 1) (Crum et al., 2007, Dubeau, 2008). The model we chose was selected in part 
to enable study of metastatic spread of ovarian cancer in addition to the clinical features of the disease. We 
chose not limit ourselves to mouse models originated specifically from either the ovary or oviduct, even 
though some may argue cells from the “true” origin may be a better or more valid model.  
While there are longstanding examples of a variety of animal models for ovarian cancer, such as 
aged egg laying hens and in vitro methods that mimic ovarian cancer interaction with the peritoneum, we 
elected to use a murine model (Lengyel et al., 2014). Genetically engineered models with mice have been 
developed to investigate ovarian cancers. These models allow for an intact microenvironment in mice, and 
the ability to investigate precursor lesions and earlier stages of disease. Some models have employed the 
use of viral genes like SV40 TAg to drive tumor development. Many models use genetic alterations 
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identified in human ovarian cancers to replicate disease of particular histologic types (Cho and Shih Ie, 
2009, Lengyel et al., 2014). For example, a combination of Tp53, Brca, and Pten deletions have been used 
to model HGSC (Cho and Shih Ie, 2009, Perets et al., 2013). Examples of drivers used to target genetic 
alterations to the ovary or oviduct include Keratin-5, MisIIr, and Pax8 among others, which are expressed 
in ovarian or oviductal epithelial cells (Cho and Shih Ie, 2009, Perets et al., 2013, Garson et al., 2012). It 
should be noted that drivers for the ovary and oviduct have issues with specificity, and often target other 
parts of the reproductive tract (Garson et al., 2012, Lengyel et al., 2014). An alternate approach used for 
model development specific to the ovary is extraction of ovarian surface epithelium to induce genetic 
alterations in vitro followed by implantation of cells under the ovarian bursa or IP in vivo. (Cho and Shih Ie, 
2009, Orsulic et al., 2002, Xing and Orsulic, 2006). Another commonly used method is injection of Cre 
recombinase adenovirus in the ovarian bursa of mice containing floxed alleles of oncogenes or tumor 
suppressor genes. This is thought to more precisely drive expression specifically at the site of the ovary 
than can be accomplished by promoter-driven expression of Cre in transgenics (Cho and Shih Ie, 2009, 
Lengyel et al., 2014, Garson et al., 2012). Both methods allow for temporal control over induction of 
mutations. Genetic models however, are subject to wait times for tumor development, and many of them 
require bursal injections which involves surgery.  
Xenograft and allograft models employing injection of tumorigenic cell lines in mice are a well-
established method of modeling ovarian cancers (Cho and Shih Ie, 2009, Lengyel et al., 2014). Many 
established human ovarian cancer cell lines have been shown to generate disseminated peritoneal disease 
in xenograft models. For xenograft, cell lines derived specifically from a patient with serous cancer can be 
selected (Lengyel et al., 2014). Syngeneic allograft models derived from mice have also been developed. 
Human or syngeneic lines have been introduced into mice via subcutaneous, intraperitoneal, or orthotropic 
bursal injection. It is of note that subcutaneous tumors grow as an individual solid tumor and do not 
resemble disseminated disease in patients. Bursal injection requires surgery to achieve. There are 
additional types of xenografts designed to capture the earlier stages of metastasis involving dissociation 
away from a primary tumor source other than bursal injection. These include the use of human or mouse 
tumor tissue, rather than cell lines, for IP injection or implantation near the ovary or under the renal capsule 
(Lengyel et al., 2014).  
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Recently, available ovarian cancer cell lines have been analyzed to determine if they are 
representative of the type of ovarian cancer being studied. This has been done through genetic profiling, 
evaluation of tumor dissemination patterns in vivo, and histological evaluation of tumors that arise from 
implantation of these human cell lines (Beaufort et al., 2014, Anglesio et al., 2013, Domcke et al., 2013, 
Mitra et al., 2015). Many of the lines were found to have a signature inconsistent with the originally 
designated type of ovarian cancer. Thus, lines may not represent the type of cancer desired or reported to 
be investigated. There has also been investigation specifically into misidentification and contamination of 
lines leading to loss of cell line integrity (Korch et al., 2012). 
A key feature of ovarian cancer models is the ability of these models to replicate metastatic spread 
in the peritoneal cavity. A variety of approaches have been used to quantify spread and the resultant tumor 
burden. Assessment of tumor burden is complicated by the fact that disease is spread throughout the 
peritoneal cavity on different organs and as numerous individual lesions on the peritoneal wall. Approaches 
to quantify tumor burden include measurement of total tumor mass, mouse mass, circumference of the 
abdomen, ascites volume, counting the number of metastases found on the peritoneal wall and organs, 
and imaging in vivo (Mitra et al., 2015, McAuliffe et al., 2012, Byrne et al., 2003, Hu et al., 2002, Sawada 
et al., 2007).  
 At the outset of my thesis research we decided to study the role of Notch3 signaling in ovarian 
cancer using both in vivo and in vitro methods to investigate disease progression and interrogate molecular 
mechanisms. Our hope was to utilize a model that replicates HGSC and its pattern of disseminated disease 
(Lengyel et al., 2014). With these points in mind, we decided to utilize ovarian cancer cell lines that would 
grow in the peritoneal cavity and on organs of the peritoneum after intraperitoneal (IP) injection, focusing 
on the stages of disease dissemination. As noted, HGSC is typically detected after metastatic spread has 
already occurred, and treatment of ovarian cancer is typically done on patients who already have multiple 
lesions in the peritoneum.  
Finally, our preference of models was influenced by a desire to use a syngeneic model so that we 
might be able to benefit from an intact microenvironment of immune competent mice. However, we initially 
compared and contrasted both murine syngeneic and human derived ovarian cancer cell lines, since the 
human lines are derived from cancer bearing patients. We chose IP injection as a method of tumor cell 
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introduction since IP introduction is less intrusive, not requiring surgery, and consistently generates 
disseminated disease. Here we describe the experiments that aimed to identify a cell line-based ovarian 
cancer mouse model that best replicated HGSC cancer, while being practical for the generation and 






Figure 3.1 Human high grade serous ovarian cancer histology and gross tumor appearance. Images 
are copied from the published review article “Ovarian Cancer Development and Metastasis” by Ernst 
Lengyel (Lengyel, 2010) from “Figure 2. Serous ovarian carcinoma metastasis”, and the published article 
“The Origin of Epithelial Neoplasms of the Ovary: An Alternative View” by Elvio G. Silva (Silva, 2016) from 
“Figure 2. Four different types of serous carcinoma”. This figure shows the histology and gross view of 
tumors in human serous cancer which we want to replicate to the best of our ability in our in vivo model. 
(A) The left panel shows a normal human peritoneal section and is described in the paper as quote, “H&E 
staining. MC (mesothelial cells), Fib (fibroblasts)”. The right panel shows the histology of a peritoneal tumor 
seed and is described as an, “Implant… in a patient with disseminated ovarian carcinoma on a background 
of normal peritoneum”. (Lengyel, 2010) (B) This image is a H&E stain of papillary serous carcinoma. (Silva, 
2016) (C) This image is described as, “Peritoneal implant with neoangiogenesis. Other smaller implants in 










 To identify appropriate models for evaluating ovarian metastatic disease, as outlined in the 
introduction, we assessed two human derived ovarian cancer lines, as well as variants of a syngeneic 
mouse model line. Our goal was to select a model for the study of the contribution of Notch3 to ovarian 
cancer disease progression and metastasis. 
The PEO1 human derived cell line did not generate IP tumors  
We attempted to model peritoneal disease with the human-derived ovarian cancer cell line, PEO1. 
The PEO1 line was developed from the ascites of a patient with poorly differentiated adenocarcinoma 
before chemotherapy resistance developed (Langdon et al., 1988, Wolf et al., 1987). Our goal was to 
determine if the PEO1 line would develop tumors from intraperitoneal injection in vivo. We lentivirally 
infected the line with a FUW plasmid containing the luciferase gene to allow for visualization with an IVIS® 
Spectrum bioluminescent and fluorescent imager (IVIS) to track tumor signal during the course of possible 
tumor development. 5 NCR nu/nu mice were injected with 10x106 PEO1 luciferase cells. We measured 
mouse circumference to assess ascites accumulation and conducted IVIS imaging weekly. The flux 
measurement (photons per second) from the IVIS bioluminescent signal dropped after initial tumor injection 
by week 1, and was never able to recover to a flux of 1x109 p/s, which we considered the minimum for 
tumor burden by 7 weeks. Mice also showed no sign of ascites by circumference increase by 7 weeks. 
While mice were no longer measured weekly, all 5 mice were kept for a total of 19 weeks without showing 
any signs of tumor burden or ascites accumulation before they were sacrificed (data not shown). It was 
determined the PEO1 model would not be a very effective or efficient model for intraperitoneal in vivo 
studies.  
The OVCAR5 human line generated small IP tumors, but little ascites 
OVCAR5 is a line derived from patient adenocarcinoma ascites (Langdon, 2004).This model was 
of interest for in vivo studies since it is known to show high NOTCH3 expression and the line reportedly 
generated metastatic peritoneal tumors in vivo similar to HGSC (Mitra et al., 2015, McAuliffe et al., 2012). 
We thought the OVCAR5 line may be useful for investigating the role of NOTCH3 in future ovarian cancer 
studies.  
To assess in vivo growth of this line, we injected 5 NCR nu/nu mice with 2.5x106 cells IP in each 
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mouse. We measured circumference and IVIS imaged once weekly. All 5 mice displayed a bioluminescent 
signal above 1x109 by 5 weeks showing tumor take for all 5 mice. By 6 weeks all mice had to be sacrificed 
due to signs of cachexia, or were found dead (see appendix A4.3 panel A for cachexia criteria (Burkholder 
et al., 2012)). One of the mice did however, display signs of fluid ascites accumulation in the peritoneum 
despite also showing signs of cachexia, like prominent skeletal features through the skin. Circumference 
measurements did not display a particular pattern in relation to time or tumor burden, indicating that mice 
did not consistently accumulate ascites (data not shown). This is consistent with a previous study that 
reported unreliable ascites formation, despite tumor formation, with the OVCAR5 model (Mitra et al., 2015). 
Mouse mass stayed fairly constant throughout the weeks until dropping for most mice in the 5th to 6th week 
due to cachexia (data not shown). This model produced small tumor seeds in the peritoneum (Figure 3.2). 





Figure 3.2 OVCAR5 luciferase intraperitoneally injected mice display peritoneal tumor burden. 
(A) Live bioluminescent imaging of mice with OVCAR5 tumors at 5 weeks post injection. Images were taken 
10 minutes after injection of each mouse with luciferin. Mouse number is shown with total flux value (p/s). 
Red circles denote area measured for flux. The signal displayed on the mice, and the color scale show 
bioluminescence measured in radiance (p/sec/cm2/sr). (B) This figure shows a partially dissected mouse 
injected with OVCAR5 (mouse #1 in panel A) sacrificed in the 6th week (44 days) post tumor injection. The 
peritoneal wall has been dissected open and pinned down. White arrows point out examples of tumor seeds 
on the peritoneal wall and on organs that have not yet been dissected. The red box demonstrates a close 
up of liver tumor seeds.   
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Syngeneic tumorigenic ID8 mouse ovarian line generates IP tumors 
We explored the use of a syngeneic line that would allow for an intact microenvironment and 
therefore better replicate patient disease. Implanting human-derived cell lines requires immunodeficient 
(nude) hosts, but a syngeneic model would allow us to use immune-competent mice while modeling stage 
III metastasis observed in human ovarian cancers. A syngeneic model would also have the benefit of 
allowing us to implant tumors into mouse models bred with defined genetic alterations. We could therefore 
decide to delete or alter genes in the Notch pathway in the mouse to investigate their role in the environment 
of ovarian cancer, or their interaction with ovarian cancer tumor cells. We were also interested in a model 
that would demonstrate HGSC disease with ascites and larger peritoneal seeds in vivo.      
The ID8 cell line is a syngeneic tumorigenic murine line that can be used to model intraperitoneal 
disease and ascites accumulation. ID8 and ID8 luciferase-containing cell lines were acquired from Dr. 
Katherine Roby at the University of Kansas Medical Center, who developed the line (Roby et al., 2000). 
ID8 is a mouse ovarian surface epithelial line that was established by removing C57BL/6 ovaries and 
collecting the normal ovarian surface epithelium. Isolated cells were passaged over 20 times in vitro. In vivo 
tumor formation was verified with passaged cells, and original passaged cells were subsequently cloned 
by limiting dilution from single cells to generate multiple different lines. One of the lines developed was ID8, 
which was then shown to be tumorigenic in both C57BL/6 and nude mice when injected IP. C57BL/6 mice 
developed tumors at approximately 114 days (~16 weeks); tumors were widespread throughout the 
peritoneum, and mice accumulated ascites fluid similar to late stage clinical cases of HGSC (Roby et al., 
2000). ID8 has been shown to model human late stage and serous ovarian cancers by peritoneal seeding. 
Based upon the number of publications using ID8, it is likely the most common syngeneic line used to model 
ovarian cancer and has been used in several studies to investigate ovarian cancer, as well as ovarian 
cancer interaction with the microenvironment (Leinster et al., 2012, Cho et al., 2013, Lengyel et al., 2014, 
Greenaway et al., 2008).  
 We performed initial evaluation of the ID8 cell line to determine the tumor take rate in our hands. 
We tested subcutaneous and intraperitoneal tumor take in NCR nu/nu mice as a first step prior to attempting 
ID8 implantation of immunocompetent mice. We injected 4 mice each with 5x106 ovarian ID8 cells either 
IP, or under the skin on both the left and right ventral side near the forelimbs. Mice were followed with IVIS 
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imaging for both types of injection weekly for 8 weeks. Intraperitoneal injected mice were also measured 
weekly, and caliper measurements were taken for subcutaneous tumors weekly.  
We observed strong tumor take in 3 of 4 intraperitoneal injected mice (Figure 3.3). All mice were 
sacrificed at day 60 to evaluate tumor development. Intraperitoneal tumor cells generated small seeds 
across the peritoneal wall. The change in mass, however, did not seem to accurately reflect the 
development of disease burden at the 60-day time point. The mass of all mice appeared to rise steadily 
over time, but accumulated varying amounts of observable ascites and in vivo bioluminescent signal. For 
example, at 8 weeks (Day 56) mouse #1 and mouse #3 had both increased mass by about 10% (9.9% and 
10.6% respectively), but mouse #1 showed no tumor burden by bioluminescent imaging, while mouse #3 
appeared positive for tumors (Figure 3.3). We also attempted assessment of peritoneal seeds in 
intraperitoneally injected mice via hematoxylin and eosin (H&E) stain, and immunofluorescent staining of 
vasculature with antibodies to CD31 (Figure 3.3). We wanted to determine whether it was possible to 
evaluate tumor seeds histologically, and if we could observe the pattern of tumor vasculature and quantify 
tumor vessels. We also wanted to determine whether our histology and gross tumors resembled HGSC.  
Tumor take occurred in all 4 subcutaneously injected mice, and mice were sacrificed at 60 days 
post injection. Subcutaneous tumors developed were small, and were deemed not sufficient for future 





Figure 3.3 ID8 luciferase intraperitoneal injected mice show tumor burden at 60 days. 
(A) IVIS luminescent image displaying all ID8 luciferase intraperitoneal injected mice at day 60. The color 
shading on mice and the luminescent scale is in radiance (p/sec/cm2/sr). Values with mouse identification 
number reflect total flux (p/s) within the designated red circles. (B) Graph displaying increase in mass in 
grams of each intraperitoneally injected mouse measured weekly compared to the first 4 weeks’ average. 
Increase in mass does not appear to correlate with bioluminescent signal for amount of tumor burden in 
mice. (C) Left panel shows the dissected right peritoneal wall of mouse #1 with little to no visible tumor 
seeds. Right panel shows the dissected right peritoneal wall of mouse #2 with several visible tumor 
seeds. (D) Hematoxylin and eosin stain of a section of peritoneal wall from mouse #3 at 20x displaying 
the histology of a tumor seed attached to the peritoneal wall. (E) Immunofluorescent staining of peritoneal 
wall section of mouse #2 at 20x. Blue signal shows DAPI staining of DNA in the cell nuclei and red 





Figure 3.4 ID8 luciferase subcutaneous injected mice show tumor burden at 60 days. 
(A) IVIS luminescent image of subcutaneous tumors at 56 days post injection. Image color and scale 
displays luminescence measured in radiance (p/sec/cm2/sr). Red circles show area measured for total flux 
(p/s). Flux vales are listed in boxes with mouse number. (B) Image of mouse #30 subcutaneous tumors at 
time of sacrifice at 60 days. Left panel shows the ventral side of the mouse pre-dissection. Right panel 




To further examine intraperitoneal take and determine take in syngeneic C57BL/6 mice we carried 
out an experiment with 4 mice each of NCR nu/nu and C57BL/6 mice injecting 4x106 ID8 cells IP into each 
mouse. Tumor signal was lost in C57BL/6 mice after 2 weeks in all mice injected. Mice were sacrificed on 
day 43 showing no visible tumor burden by IVIS (data not shown). NCR nu/nu mice were allowed to develop 
tumors for longer than in the previous experiment to determine if higher tumor burden and ascites would 
form, and to let tumors develop closer to the timeline originally reported with ID8 development. Mice were 
sacrificed between days 106 and 120. We monitored tumor burden via bioluminescent imaging weekly. We 
observed that tumor burden appeared to rise progressively through the experiment, but then started to 
reduce once the mice accumulated larger amounts of ascites at time points around 12 to 13 weeks. Mice 
developed larger peritoneal tumor seeds than in the shorter experiment, and developed more visible seeds 
on other peritoneal organs (Figure 3.5). One drawback to this model was that it took up to 120 days to 






Figure 3.5 Time course analysis of tumor burden in ID8 luciferase intraperitoneally injected mice. 
(A) Live images of IVIS tumor burden at weeks 1, 12, and 14 in NCR nu/nu IP injected mice. Peak signal 
occurs around week 12 and then decreases with increasing ascites. (B) Weekly tumor burden displayed by 
total flux measurement of luminescence plotted for all 4 intraperitoneally injected NCR nu/nu mice. (C) 
Photographs from dissection of NCR nu/nu IP injected mouse #2. (i) Ventral mouse before dissection. (ii) 
Skin is dissected back, but peritoneal wall left intact. Bloody ascites is visible through the peritoneal wall. 
(iii) Peritoneal wall is dissected back and ascites fluid has been removed. Tumors can be seen on the 
peritoneal wall and organs. (iv) Close up photograph of ID8 tumor seeds on the intestinal mesentery. (v) 
Close up photograph of ID8 tumor seeds on the peritoneal wall.   
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ID8 IP2, an ID8 subline, generates similar tumor burden to ID8 at earlier time points   
 We completed in vivo examination of the ID8 IP2 line, a subline of ID8 acquired from Dr. Jill Slack-
Davis at the University of Virginia School of Medicine. This subline was created by developing 
intraperitoneal tumors in vivo with the original ID8 line in C57BL/6 mice, and subsequently collecting and 
culturing the tumor cells in vitro. ID8 IP2 were passed through mice followed by culturing twice, thus the 
name “IP2” (Nakayama et al., 2015). ID8 IP2 had accelerated development of disease burden compared 
to the original ID8 line, with endpoint disease for ID8 IP2 at approximately 8-10 weeks, as opposed to 
approximately 20 weeks for ID8. This reduces tumor and ascites development time by half, while still 
resulting in a similar pattern of disease.  
We modified the ID8 IP2 line to express luciferase by lentiviral infection with a FUW plasmid 
containing luciferase, mCherry, and puromycin resistance genes. Presence of luciferase was confirmed in 
vitro using Promega Dual-Luciferase® Reporter Assay System reagents, and visualization of mCherry 
expression was confirmed with fluorescence microscopy after lentiviral infection (data not shown).   
We attempted in vivo tumor growth studies in both NCR nu/nu and C57BL/6 mice, to establish 
whether IP injection of ID8 IP2 luciferase (ID8 IP2 luc) cells generate metastatic peritoneal disease and 
ascites accumulation as expected. We intraperitoneally injected 4 NCR nu/nu and 4 C57BL/6 mice with 
2x106 ID8 IP2 luc cells in sterile phosphate buffered saline. Mice were followed with weekly IVIS and mass 
measurements. Some mice developed cachexia; among these some of the cachexic mice developed 
ascites and some did not. This pattern also occurs in human patient disease, where not every ovarian 
cancer patient develops ascites (Puls et al., 1996). At the time of sacrifice, the signal for the peritoneal wall 
tumor burden was assessed by IVIS. Since completing this investigation, other similar methods to track 
tumor burden at time of sacrifice via tumor reporter in dissected tissue of mice with ovarian cancer have 
begun to be used confirming our technique (Lewellen et al., 2016). Tumor sections from NCR nu/nu mice 
were stained for histology by H&E, as well as with endomucin by immune-fluorescence to detect 
vasculature.  
3 of the 4 NCR nu/nu injected mice developed tumor burden and showed bioluminescent signal on 
weekly imaging and at endpoint. Mice with burden developed ascites, and displayed tumors on the 
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peritoneal wall and organs. Peritoneal wall luminescence exemplifying tumor burden at end point appeared 
to correspond to areas of tumor burden observed visually (Figure 3.6).    
C57BL/6 ID8 IP2 luc injected mice showed poor bioluminescent signal via IVIS imaging, but 3 of 
the 4 mice developed ascites. One expects bioluminescent signal to decrease after large amounts of ascites 
accumulation develop, as seen in the ID8 luc experiments. When ID8 IP2 luc was implanted in C57BL/6 
mice the IVIS signal drops below that of the initial tumor take, as expected, but then the signal remains low 
for the duration of the experiment until endpoint without ever recovering to initial levels. In the nude mice, 
as with the ID8 luc, once the tumor burden begins to rise it continues until ascites accumulation occurs 
(Figure 3.5, data not shown). For the ID8 IP2 luc experiments in C57BL/6, upon imaging the peritoneal wall 
at sacrifice, it was seen that only a subset of tumors visualized on the peritoneal wall were bioluminescent 
(Figure 3.7).  
A second experiment where an additional 4 C57BL/6 mice were injected with 2x106 ID8 IP2 luc 
cells displayed similar results where the bioluminescent signal did not correspond to all of the tumor seeds 
for each mouse at endpoint (Figure 3.8). In this second experiment, we measured circumference of each 
mouse weekly to measure ascites accumulation throughout the experiment. We calculated the percent 
increase in circumference at endpoint to represent the amount of ascites accumulation over the course of 
tumor development (Figure 3.8). The percent increase was determined by the circumference measurement 
around the widest part of the mouse abdomen at a given time point compared to the average circumference 
over the first 4 weeks before ascites accumulation occurs. We were able to remove ascites with a syringe 
through the peritoneal wall and measure the volume. Increase in ascites both visually and by volume 
appears to correlate with circumference, and may be useful to measure in this model.      
The ID8 IP2 luc model looked promising as a model to evaluate ovarian cancer by following tumor burden 
with IVIS, but only in NCR nu/nu nude mice. These mice were able to generate tumors and ascites similar 
to the ID8 model, but in a shorter time frame. The histology of tumor seeds from both ID8 luc and ID8 IP2 
luc appear similar indicating that ID8 IP2 luc are similar to HGSC since it has already been shown ID8 are 
similar to HGSC (Cho et al., 2013, Greenaway et al., 2008).  In addition, in nude mice we were able to 
follow live tumor burden by bioluminescent imaging. We concluded that circumference measurement may 
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be a good way to measure ascites accumulation that is representative of disease burden and that tumors 





Figure 3.6 The ID8 IP2 luciferase line produces tumors when injected intraperitoneally in less time 
than the ID8. (A) IVIS imaging displaying tumor burden at 1 week (top panel) and 6 weeks (bottom panel). 
(B) Dissected peritoneal wall of mouse number 12 at endpoint on day 46. Left panel displays photograph 
of tumors in dissected mouse. Right panel shows IVIS imaging directly after sacrifice. Colored tumor burden 
signal on IVIS (radiance) at endpoint appears to match with tumors seen in the photograph of peritoneal 
wall. (C) Mouse number 11 peritoneal wall ID8 IP2 luc tumors stained with hematoxylin and eosin. Left 
panel shows a 10x photograph demonstrating tumor seeds infiltrating the peritoneal wall. Right panel shows 
a 20x photograph of a separate region of peritoneal wall and tumors attached to the surface. ID8 IP2 luc 
generate tumors that are consistent with the formation of ID8 tumors and with similar histology to ID8 tumors 
(Figure 3.3). (D) Mouse number 11 peritoneal wall sections with endomucin immunofluorescent staining for 
blood vessels. An example of the architecture of the tumor vs. the peritoneal wall in these 
immunofluorescent images is designated in (i). (i-iii) 10x section of peritoneal wall shows blood vessels by 
endomucin stain at the edge of the tumor seed on the wall. (iv-vi) 20x photo of area where peritoneal wall 
and tumor seed meet. This area appears rich in vasculature compared to the tumor seed and the rest of 






Figure 3.7 ID8 IP2 luc tumors may lose their bioluminescence when implanted intraperitoneally in 
vivo in immunocompetent mice. (A) Top panel shows mice 4 days after tumor injection and initial tumor 
take. Bottom panel shows mice at 9 weeks. Bioluminescent signal is reduced from initial tumor take despite 
ascites accumulation indicating disease development. (B) Graph displaying the measurable weekly tumor 
burden by bioluminescence for each mouse. Measured bioluminescence does not show a consistent 
pattern of growth. (C) Left panel shows dissected mouse #3 peritoneal wall. Right panel shows the same 
mouse imaged by IVIS for tumor burden. Not all tumors visualized show bioluminescent signal. This is most 
apparent on the diaphragm and the mouse’s left peritoneal wall. Arrows denote some examples of these 





Figure 3.8 Bioluminescent evaluation of ID8 IP2 luciferase tumors implanted in C57BL/6 does not 
correlate with tumor burden but abdominal circumference measurement relates to ascites 
accumulation. (A) The top 2 panels show mouse #1 dissected at time of sacrifice. Despite the development 
of many tumors (left panel photo), there is no bioluminescent signal visualized on IVIS (right panel IVIS 
image). Bottom two panels show mouse #10 at the time of sacrifice. Tumors seen in photograph (left panel), 
appears to correlate with bioluminescent signal (colored radiance in the right panel). (B) All 4 mice at 9 
weeks post tumor injection side by side for size comparison. Boxes show the total flux measured for 
bioluminescence per area in the circle (p/s). The percent increase in circumference at 9 weeks is displayed 
below each mouse. Increase in circumference does not appear to correlate with presence or absence of 
bioluminescent signal. (C) Photographs at time of sacrifice for mice #1 and #2. Note that mice were 
sacrificed at different time points (days 105 and 70 for mouse #1 and mouse #2 respectively) showing 
increase in ascites over time after injection. The percent increase in circumference at the time of sacrifice 
and the approximate volume of ascites collected from each mouse is displayed in the chart. The percent 
increase in circumference appears to correlate with amount of ascites.  
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Generation of an ID8 IP3 subline did not affect tumor development or bioluminescent tracking in 
syngeneic mice 
To determine if there was a way to optimize the ability to track ID8 IP2 luc tumor seeds in vivo in 
immunocompetent C57BL/6 mice, we attempted another passage of the cells through mice by collecting 
tumor cells from a tumor bearing C57BL/6 mouse with high bioluminescent signal. We collected tumor cells 
from ascites, as well as from tumor seeds on the peritoneal wall. We subsequently sorted isolated tumor 
cells using flow cytometry by the mCherry in the original infected plasmid with the luciferase. Sorted cells 
were then cultured in vitro. We assessed the ability of these cells to develop tumors, and bioluminescent 
signal related to those tumors in mice. We identified these newly sorted cells as ID8 “IP3” luc cells. We 
injected 4 mice with ID8 IP3 luc ascites generated cells, and 4 additional mice with ID8 IP3 luc peritoneal 
wall tumor derived cells. All mice were injected with 2x106 cells.  We observed, however, that if tumors 
formed, there was a loss of bioluminescent signal with both types of tumors developed from cells derived 
from ascites and peritoneal seeds (Figure 3.9). There appeared to be no correlation between the live IVIS 
bioluminescent signal and the resultant amount of tumor burden observed at endpoint. All mice showed 
little to no signal on IVIS imaging even though they displayed varying amounts of tumor seeds upon 
dissection. These ID8 IP3 luc lines also generated fewer mice with tumor burden at similar time points to 





Figure 3.9 ID8 IP3 luciferase lines do not generate peritoneal tumors that display consistent 
bioluminescence with whole mouse live imaging. (A) Top panel shows mice intraperitoneally injected 
with ID8 IP3 luciferase ascites derived cells. The lower panel shows the mice injected with ID8 IP3 luciferase 
peritoneal tumor seed derived line. At 6 weeks, little bioluminescent signal by radiance is displayed. (B) 
Ascites derived ID8 IP3 luciferase tumor bearing mice. The left 2 panels show mouse #2 and mouse #20 
at the time of sacrifice, and the percent increase in circumference at that time. The right two panels show 
the dissected left peritoneal wall of mouse #2 and mouse 20. There is a wide variation in the amount of 
visible tumor burden generated in injected mice on the peritoneal wall showing less consistent results in 






 The experiments we conducted using the ID8 IP2 luc model generated tumors in vivo more quickly 
than other tested cell lines, such as ID8, while also generating intraperitoneal tumor seeds and ascites 
accumulation. Unfortunately, we found that the ability to track ID8 and subline tumors in C57BL/6 mice via 
bioluminescence was unreliable. One possible explanation for this loss of signal in tumors could be due to 
the interaction of these cells with host cells of the mice silencing the signal by one or several mechanisms. 
Previous analysis in one study has demonstrated similar loss of a fluorescent signal in a colon cancer model 
in immune competent rats (Garcia-Olmo et al., 2008). They observed a population of non-fluorescent cells 
within tumors, and a greater reduction in the proportion of fluorescent-positive tumor cells over progressive 
weeks of tumor development in vivo. Furthermore, they identified non-fluorescent tumors that demonstrated 
evidence of the GFP gene upon PCR analysis. In addition, none of the metastases identified in lymph nodes 
or the lungs in their study showed observable fluorescence (Garcia-Olmo et al., 2008). Eventually over time 
the tumor cells even lost the GFP gene, but still contained mutations from the original tumor not in the host 
cells. The authors speculate that recruitment of host cells to the tumor may be involved in generating tumor 
cells with no fluorescence (Garcia-Olmo et al., 2008). Perhaps host cells are generating additional tumor 
cells, or the immune system of these rats is silencing the expression of the reporter. Another study showed 
an increase in tumor cells and metastases observed by GFP fluorescence in a murine colon tumor model 
in SCID mice compared to C57BL/6 and nude mice at later time points suggesting a role of the immune 
system in silencing GFP positive tumor cells (Steinbauer et al., 2003). One study also demonstrated that 
three different syngeneic cancer lines lentivirally infected with a luciferase-GFP reporter lost 
bioluminescence in metastases in wild type albino C57BL/6 or FVB/N mice (Day et al., 2014). Furthermore, 
tumors generated in vivo from re-implantation of cells from bioluminescent metastases did not retain the 
same ability to bioluminesce. This seems similar to our unsuccessful attempt to increase bioluminescence 
with generation of the ID8 IP3 luciferase lines. Since the fluorescence used in these studies and the 
bioluminescence we use are introduced and act in similar ways as reporters in tumor cells described in the 
literature, we hypothesize similar mechanisms may be affecting signal from ID8 IP2 tumor cells grown in 
C57BL/6 mice. Perhaps the reliance of the ovarian model on metastatic tumor formation without a primary 
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solid tumor increases our loss of bioluminescent signal, as these studies indicate a particular loss of reporter 
activity related to metastases.  
Based on our results demonstrating this lack of reliable bioluminescent signal to track tumor burden 
in C57BL/6 mice, we decided to conduct future experiments in NCR nu/nu mice. Despite the lack of a 
complete tumor microenvironment in nude mice, we wanted to be able to follow bioluminescent signal 
throughout disease development, and to assess tumor burden at endpoint in the peritoneal wall and other 
organs.       
 We also chose an ovarian derived mouse model (ID8) over a fallopian derived model based on the 
lack availability of fallopian derived mouse cell lines suitable for IP injection available at the time of 
experiments. We have more recently acquired murine fallopian derived tumorigenic cells lines from Dr. 
Joana Burdette at the University of Illinois at Chicago, which could be tested in the future as a model 
(Endsley et al., 2015). In addition, the human derived lines we tested failed to generate tumors as quickly 
and efficiently as our ID8 IP2 luc model, and ID8 have been shown to have characteristics such as 
morphology of tumors, ascites accumulation, and histological features similar to HGSC (Cho et al., 2013, 
Greenaway et al., 2008).       
Thus, the ID8 IP2 luc in NCR nu/nu mice model was chosen to investigate Notch3 signaling in 
ovarian cancer based on the ability to replicate HGSC and generate tumors and ascites in a much faster 
time period, with injection of fewer tumorigenic cells. Using the ID8 IP2 line, we observed large tumor seeds 
and more robust ascites development at similar time points than that of other tumor models we tested. 
Importantly, studies of ID8 IP2 luc in NCR nu/nu allowed us to follow tumors by IVIS throughout the 
development of tumors and at end point.  
   






NOTCH3 INTRACELLULAR DOMAIN AFFECTS ASCITES ACCUMULATION 




NOTCH3 expression has been found to associate with the severity of ovarian cancer. Elevated 
NOTCH3 expression in ovarian cancer patients has been linked to shorter overall survival and more 
advanced tumor stage, grade, and ascites accumulation (Hu et al., 2014, Jung et al., 2010, Liu et al., 2016, 
Park et al., 2010, Park et al., 2006b). NOTCH3 expression is correlated with chemotherapy resistance and 
recurrent tumors in patients (Park et al., 2010, Rahman et al., 2012).     
NOTCH3 is thought to promote viability of ovarian cancer cells. Cell lines with high Notch3 
expression have been shown to display reduced viability and increased apoptosis when NOTCH3 is 
inhibited by either GSI or siRNA knockdown (Hu et al., 2014, Park et al., 2006b). In particular, NOTCH3 
has specifically been linked to viability of ovarian tumor cells being treated with chemotherapeutic agents 
and tumor cells that have demonstrable resistance to chemotherapy. Ovarian cancer cells grown in vitro 
high in NOTCH3 treated with platinum or already chemotherapy resistant have reduced viability, increased 
apoptosis, and display a reduced IC50 of cancer cells in the presence of a Notch inhibitor (Park et al., 2010, 
Rahman et al., 2012). Under treatment with chemotherapy, ectopic overexpression of NOTCH3 intracellular 
domain (ICD) in ovarian cancer cells exhibit increased viability, reduction in apoptosis, increase in IC50, as 
well as increased expression of proteins involved in epithelial to mesenchymal transition (Gupta et al., 2013, 
McAuliffe et al., 2012, Park et al., 2010). NOTCH3 expressing ovarian cancer lines implanted in mice 
respond to combined chemotherapy and Notch inhibition, as exhibited by a reduction of tumor burden and 
tumor microvasculature density on staining (Groeneweg et al., 2014a, Hu et al., 2014, McAuliffe et al., 2012, 
Shah et al., 2013).  
Our goal is to discover the mechanism by which NOTCH3 expression in ovarian cancer cells 
contributes to increased tumor development, viability of cancer cells, poor survival, and chemotherapy 
resistance. This understanding will lead to better treatment strategies and shed light on major hurdles in 
treatment which arise from late stage of detection, poor response to chemotherapy, and high rate of 
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recurrence of ovarian cancers. We will confirm the previous aforementioned results which used human 
ovarian cancer cells with high NOTCH3 by using a ID8 IP2 mouse ovarian cancer cell lines. ID8 IP2 have 
the ability to seed intraperitoneal tumors in mice that display similarities to HGSC. This line has been 
programmed to express luciferase (ID8 IP2 luc), thus optimizing our ability to follow tumor development 
(see Chapter 3). ID8 IP2 develop tumors faster than the rates of tumor growth described for other lines (see 
Chapter 3). We hypothesize that introduction of ectopic NOTCH3 ICD into the mouse ovarian surface 
epithelial cell line ID8 IP2 luc will induce growth, increased viability, and chemotherapy resistance of these 
tumorigenic cells. Furthermore, we hypothesize that these Notch3-activated ovarian cancer cells will 






ID8 IP2 cells have low expression of Notch3 
 We were seeking to the confirm the published effects of NOTCH3 in human ovarian cancer cells 
so we could subsequently investigate the mechanism of the influence of Notch3 upregulation in ovarian 
cancer in mice. We explored the use of the ID8 IP2 line to address this goal since we had previously 
determined its efficacy in producing intraperitoneal tumors in vivo. We evaluated the level of Notch protein, 
Notch pathway component genes, and Notch ligand genes present in the ID8 IP2 line.  Ovarian cancer cell 
lines with known expression of Notch pathway components were used as controls (Figure 4.1). Semi-
quantitative RT-PCR indicated no observable Notch3 was present in ID8 IP2 cells upon visualizing agarose 
gel electrophoresis with PCR products. However, Notch receptors Notch1, Notch2, and Notch4 were 
present in ID8 IP2 cells. Ligands present include Jag1 and Dll1, however Dll4 was not observed. These 
results indicate expression of Notch pathways genes in the ID8 IP2 lines at the RNA level (primers Appendix 
Table A4.1). The lack of NOTCH3 protein expression in the ID8 IP2 line was confirmed by western blot 
analysis using known NOTCH3 expressing human ovarian cancer lines as a positive comparison (Figure 
4.1) (McAuliffe et al., 2012, Park et al., 2006b, Hu et al., 2014). The parental ID8 line also appears to have 
low levels of NOTCH3 observed on western blot (Figure 4.1), but expresses fewer other Notch receptors, 
which may confound our results. However, using the ID8 IP2 line is preferable to the original ID8 line, since 
it develops tumor seeds more efficiently and faster; an advantage for future in vivo studies (Chapter 3). ID8 
IP2 lacked detectable expression of NOTCH3. As noted, NOTCH3 is specifically linked to high grade serous 
ovarian cancer. We therefore concluded that ID8 IP2 was an appropriate model for investigating NOTCH3 






Figure 4.1 NOTCH3 is not notably expressed in ID8 IP2 ovarian tumorigenic cells.  
ID8 IP2, its parental line ID8, and other cells lines with known Notch receptor and ligand status were 
evaluated. HUVEC are human endothelial cells known to express Notch1, and 4, but not Notch3 (Kofler et 
al., 2015). HBVP are human pericytes known to express high levels of Notch3 (Kofler et al., 2015). Lanes 
marked H2O are negative for cDNA and molecular grade water was added instead of cDNA sample. Primers 
are listed in Appendix Table A4.1. (A) Semiquantitative RT-PCR demonstrating cDNA for Notch1, Notch2, 
and Notch4 receptors, but no observable Notch3 cDNA in ID8 IP2 cells. ID8 IP2 cells also show Jagged1 
and Delta-like 1 ligand expression. (B) Western blot demonstrating lack of NOTCH3 protein expression in 
ID8 IP2 and ID8 IP2 luc ovarian cancer lines. SKOV3 are known to be NOTCH3 negative. All other non-
ID8 lines have previously been shown to express NOTCH3 (Park et al., 2006b, McAuliffe et al., 2012, Hu 
et al., 2014).  
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Generation and characterization of NOTCH3 expressing ID8 IP2 cells 
Human high grade serous ovarian cancers display increased expression of full length Notch3 or 
increased copy number of the Notch3 gene. We introduced the Notch3 intracellular domain into ID8 IP2 
cells, as the intracellular domain ensures robust ligand-independent signaling. Using the intracellular 
domain removes the requirement for ligand interaction and the S1-S3 cleavage events needed for Notch3IC 
to activate signaling in the nucleus (Kopan and Ilagan, 2009, Radtke et al., 2005). Robust and constitutive 
Notch3 signaling can therefore occur without direct contact with ligand presented by other ID8 IP2 cells or 
other potential ligand-presenting cells in the environment. In preliminary experiments, we have introduced 
full length Notch3 into ID8 IP2 cells, and while protein expression was confirmed by western blot, active 
signaling induced by ligand from tumor or other cell types was never confirmed (Appendix Figure A4.1). 
 We engineered the ID8 IP2 luciferase (ID8 IP2 luc) line to drive the expression of the Notch3 
intracellular domain. Cells were lentivirally infected with pCCL plasmids containing human 
phosphoglycerate kinase promoter upstream of either the mouse Notch3 intracellular domain (Notch3IC) 
or empty vector (Control) (Dull et al., 1998). The Notch3IC construct was modeled after published Notch3 
ICD (Beatus et al., 1999) and contains a C-terminal HA tag fused to the Notch3 intracellular domain 
centered around the Ankyrin repeats ( codons 1664-2318 (Lardelli et al., 1996)) followed by an Internal 
Ribosome Entry Site (IRES) GFP (Kofler et al., 2015). The control vector used was the unmodified pCCL 
plasmid with only the multiple cloning site downstream of the promoter. A total of five independently 
generated cell lines were used as Notch3IC and Control biological replicates.  
We confirmed the presence of Notch3 mRNA and protein in lentivirally infected cells to ensure 
effective expression was achieved. Western blot analysis using antibodies against the NOTCH3 ICD 
demonstrated expression of NOTCH3 ICD in Notch3IC cells (Figure 4.2). Quantitative RT-PCR confirmed 
the presence of Notch3 mRNA in these lines (Figure 4.2, Table 4.1). We confirmed activation of Notch3 
signaling across all five sets of lines by demonstrating increased expression of Notch3 downstream targets 
relative to Control lines via RT-qPCR (primers Appendix Table A4.2). A significant increase in downstream 
Notch3 targets Hey1 and HeyL was seen compared to Control (Figure 4.2). We observed very little change 
in Hes1, which is a known target of other Notch receptors but does not typically respond well to Notch3 
signaling, indicating that our Notch activation was specific to Notch3 (Beatus et al., 1999, Shimizu et al., 
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2002, Ong et al., 2006). We were therefore confident that Notch3 specific signaling was active in these ID8 
IP2 luc Notch3IC cell lines. Since Notch3 signaling was successfully induced in ID8 IP2 luc, the matched 
Notch3IC and Control lines were used to evaluate the growth, tumorigenic, and metastatic properties 







Figure 4.2 Notch3 expression and signal activation is present in lentivirally infected ID8 IP2 luc cells. 
(A) Western blot demonstrating increased NOTCH3 ICD in Notch3IC infected ID8 IP2 luc compared to 
Control infected cells. OVCAR3, A2780 and SKOV3-IP1 are used as positive and negative controls as 
described above. (B) RT-qPCR demonstrating Notch3 and downstream Hey targets increase in gene 
transcripts for Notch3IC compared to Control. No induction of Hes1 was observed. Graph displays the 
average of the 5 sets of infected lines. Notch3 primers are targeted to sequence in the intracellular domain, 
and therefore should recognize both endogenous and exogenous Notch3. Primer sequences are in 





ID8 IP2 Luc Notch3 HeyL Hey1 Hes1 
Set 1 67.52 4219.01 579.49 2.43 
Set 2 13.23 3636.05 198.33 1.35 
Set 3 118.64 13771.97 476.06 1.15 
Set 4 164.50 17569.83 560.19 0.93 
Set 5 38.70 667.23 346.19 1.44 
 
Table 4.1 Notch3 and downstream target activation for each lentiviral infected line set shows 
consistent activation of the Notch pathway. The difference between Control and Notch3IC expression 
of Notch3 and downstream target genes in each set of lentiviral infections, as measured by RT-qPCR. 
Notch3, HeyL, and Hey1 all increase in fold change compared to Control, while Hes1 shows little fold 




NOTCH3 ICD expression did not promote significant changes in ID8 IP2 growth properties 
We first sought to confirm an increase in growth of ovarian cancer cells based on the evidence in 
the literature for a role of Notch3 in the growth and viability of different ovarian cancer cell lines. ID8 IP2 luc 
Notch3IC and Control lines were evaluated for viability/proliferation by seeding 2.5x103 cells per well and 
staining after 48 hours with WST-8, a tetrazolium salt, which indicates viable cells (Berridge et al., 2005). 
We also evaluated anchorage independent growth by quantitating colony formation on soft agar. Based 
upon previous studies, we expected that expression of NOTCH3 ICD would increase the viability and colony 
forming ability of ID8 IP2 ovarian cancer cells. The results, however, indicated no significant difference in 
the viability or anchorage independent growth of Notch3IC activated ovarian cells (p = 0.9397, p = 0.9927 
Welch’s t-test, Figure 4.3).  
After determining that there was no apparent increase in viability for NOTCH3 ICD expressing cell 
lines, we considered this may be due to a heterogeneous population of Notch3IC infected and non-infected 
cells. We therefore sought to purify a set of cells that uniformly expressed Notch3IC at high levels. Using a 
freshly infected matched set of Notch3IC and Control ID8 IP2 lines, we sorted the Notch3IC line for GFP, 
which has an IRES-GFP and therefore co-expressed with NOTCH3 ICD (Appendix Figure A4.2). The 
Control cell line did not express GFP and thus were sorted for mCherry (expressed from a previously 
infected construct) to ensure similar treatment of Notch3IC and Control ovarian cancer cell lines. The GFP-
high expressing population therefore should have higher NOTCH3 ICD expression, since these are cells 
that incorporated the pCCL plasmid. We then compared the FACS-sorted Notch3IC to Control by a WST-
8 assay to determine if uniformly positive NOTCH3 cells would now display an increase in viability. 
However, Notch3IC activated cells displayed significantly reduced cell count determined by 450nm 
absorbance of WST-8 indicating a loss of living cells compared to Control (p = 0.0022, Welch’s t-test) 
(appendix Figure A4.2). FACS-sorted lines were analyzed in additional assays as well that demonstrated 
further results differing from data collected on the heterogeneous population of infected cells (appendix 
Figure A4.2). We interpreted these results as evidence that very high levels of NOTCH3 ICD may be 
deleterious to cell viability.  
We sought to confirm the effect of NOTCH3 expression on chemotherapy resistance previously 
described in the literature using our ID8 IP2 luciferase lines. We expected Notch3IC would display higher 
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amounts of cell survival/growth of cells compared to Control in the presence of chemotherapy. We therefore 
evaluated the effects of cisplatinum treatment on the growth of ID8 IP2 luc Notch3IC and Control ovarian 
cancer cells in vitro. Both lines were treated with cisplatinum at the following doses: 0μM, 2μM, 4μM, 8μM, 
and 16μM. The number of remaining live cells after cisplatinum treatment was assessed with a DIMSCAN 
instrument. The DIMSCAN cytotoxicity assay is a semiautomatic fluorescence digital imaging system, which 
quantifies viable cells using a fluorescein diacetate dye read by the instrument (Frgala et al., 2007, 
Keshelava et al., 2005). No significant difference was observed between ID8 IP2 luc Notch3IC and Control 
lines when evaluating the number of living cells after culture in the presence of cisplatinum. The LogIC50, a 
measure of the inhibitory concentration at which 50% of cells are inhibited/ non-viable, was not significantly 
different between Notch3IC and Control cell line dose curves where LogIC50 for Notch3IC and Control was 




Figure 4.3 There is no significant change in the growth and viability of Notch3IC ID8 IP2 luc ovarian 
cancer cells in vitro. (A) A WST-8 assessment of growing Notch3IC and control cells showed no difference 
in the absorbance of WST-8 and therefore the number of viable cells after 48 hours of growth (p = 0.9397, 
Welch’s t-test). (B) Colony formation in soft agar stained with MTT showed no significant change in the 
number of colonies or total colony area per well for Notch3IC compared to Control (p = 0.9927, p = 0.8744 
Welch’s t-test). (C) There is no significant difference in the response to cisplatinum chemotherapy treatment 
of Notch3IC and control cells for a direct count of surviving cells or for the log10 transformed and normalized 
data (p = 0.9466 nonlinear regression comparison of fit Y=100/(1+10^((X-LogIC50)))).  
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NOTCH3 ICD promotes ascites accumulation and reduces survival in mice bearing ID8 IP2 luc cells 
Based on previous data demonstrating a correlation between NOTCH3 expression and poor patient 
survival we sought to assess the effects of Notch3 activation on tumor development and metastasis in mice. 
Despite the lack of effect in vitro, we hypothesized that Notch3 signal activation may influence ovarian 
cancer cell growth and metastatic spread when implanted in mice.  
While ID8 cells are derived from C57Bl/6 mice and can be implanted into syngeneic 
immunocompetent mice, we decided to use nude mice to better track tumor burden via luciferase 
visualization throughout the experiment and at endpoint by IVIS Spectrum bioluminescent imaging (see 
Chapter 3). This choice was made as a result of apparent “quenching” of luciferase signal when ID8 IP2 
luc cells were implanted in C57BL/6 mice (Chapter 3).  
NCR nu/nu mice were intraperitoneally injected with 2x106 ID8 IP2 luc Notch3IC or Control ovarian 
cancer cells. Successful formation of disseminated tumors from injected cells (i.e. “tumor take”) was 
determined by weekly luciferin injection and imaging via IVIS spectrum. In addition to IVIS tumor burden 
assessment, ascites accumulation was determined using a circumference measurement around the 
abdomen of mice. Circumference measurements were done weekly and compared to the average of the 
circumference measured during the first 4 weeks post tumor injection in the same mouse, before high tumor 
take or ascites accumulation is normally observed. Mice were sacrificed when they reached a 25% or more 
increase in abdominal circumference. A small number of mice from both groups were also sacrificed based 
on cachexia criteria, but all tumor bearing mice were included in assessment. Cachexia was qualitatively 
determined by body condition score below 3 (Ullman-Cullere and Foltz, 1999) (Appendix Figure A4.3).  
Notch3IC tumor bearing mice displayed reduced survival compared to Control using a Gehan-
Breslow-Wilcoxon test (p = 0.0183, Figure 4.4). No significant difference was observed when analyzed with 
a Log-rank/Mantel-Cox assessment (p = 0.0592, Log-rank for the same experimental data). The Gehan-
Breslow-Wilcoxon test does not assume a consistent hazard ratio across the experiment and weights early 
time points more, so a significant result with this test suggests that there is a greater difference in early 
deaths between groups (Martinez and Naranjo, 2010, Tarone and Ware, 1977). A total of 52 tumor-bearing 
mice were assessed (27 control and 25 Notch3IC). The median survival of Notch3IC mice was 4 days 
shorter than Control mice (65 vs. 69 days). In addition to the Kaplan Meier analysis, the mean survival of 
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Control mice was 72 days, while the mean Notch3IC mice survival time was 65 days (p = 0.0356, t-test) 
indicating the mice with Notch3IC active tumors succumb to disease a week sooner.  
We compared the amount of ascites accumulation, an indirect measure of tumor burden, between 
Notch3IC and Control mice at 8 weeks after tumor injection. This time point was chosen as this is the time 
when we first started sacrificing mice due to an increase in circumference greater than or equal to 25% in 
the survival study (Figure 4.4). Circumference of each mouse was assessed to determine ascites 
accumulation for 69 total mice (35 Control, 34 Notch3IC). Notch3IC mice displayed significantly increased 
circumference by 5% over control, where the average increase in circumference for Notch3IC mice was 
14.3% compared to the Control mice mean of 8.9% (p = 0.0423, t-test on direct data, p = 0.0017 on Log10 
transformed data. Figure 4.4). The increase in absolute circumference was significantly increased for 
Notch3IC tumor bearing mice compared to Control; Notch3IC tumor bearing mice displayed an average 
increase of 1.08cm, whereas Control mice which showed an average increase of 0.69cm in circumference 
(p = 0.0386, Welch’s t-test, Figure 4.4).  
In one of the independent trials, with a cohort of 17 tumor bearing mice (8 Control and 9 Notch3IC), 
we assessed the peritoneal wall and ovary tumor burden at endpoint by measuring bioluminescent signal 
of these organs with the IVIS. We compared the total luminescent signal between Notch3IC and Control 
mice that were all sacrificed and measured at 8 weeks. There appeared to be a potential trend indicating 
more bioluminescent signal from tumors in Notch3IC tumor bearing mice, however, there was no significant 
difference between the tumor burden on the peritoneal wall or right ovary and uterine horn in Notch3IC 
mice compared to Control in this smaller set of assessed mice (p = 0.1686, p = 0.2015 respectively, 
Appendix Figure A4.4). 
Taken together, this data show that Notch3IC activation in ID8 IP2 ovarian tumors reduces survival 
of the tumor bearing mice and leads to an increase in ascites accumulation. We interpreted these results 
as demonstration that NOTCH3 ICD expression my promote metastatic spread or influence the process of 




Figure 4.4 Notch3IC causes a reduction in mouse survival and an increase in disease burden in 
vivo. (A) Kaplan Meier survival curve demonstrating a significant decrease in survival for Notch3IC mice 
(p = 0.0183, Gehan-Breslow-Wilcoxon). (B) A significant increase in circumference and therefore ascites 
accumulation is observed in Notch3IC tumor bearing mice compared to Control at the 8-week time point (p 
= 0.0423, Welch’s t-test on direct data, p = 0.0017 Welch’s t-test on log10 transformed data). The log 
transformed data displays the distribution tumor bearing mouse population for Notch3IC and Control. (C) 
There is a significant difference in the absolute increase in circumference compared to pre-tumor burden 
circumference between Notch3IC and Control at 8 weeks. The increase in circumference is significantly 
higher in the Notch3IC tumor bearing mice (p = 0.0386, Welch’s t-test). (D) Representative images of ID8 
IP2 luc Control and Notch3IC tumor bearing mice sacrificed at 8 weeks. The Control mouse on the left has 
a 7.5% increase (0.5cm) increase in circumference, while the Notch3IC mouse on the left has a 11.6% 
increase (0.9cm) increase in circumference. These mice demonstrate an approximation of the visual 
increase in disease burden displayed in B and C. The Notch3IC tumor bearing mouse also displays 
increased signs of underconditioning (prominent spine) despite ascites accumulation increasing mouse 





We demonstrated that the ID8 IP2 ovarian cancer line has little to no expression of NOTCH3 and 
were able to robustly induce Notch3 signaling in these cells. Ectopic expression of NOTCH3 ICD in ID8 IP2 
cells did not significantly alter the in vitro growth properties or survival of these mouse ovarian surface 
epithelial cells. This was contrary to previous results with other ovarian cancer cell lines, which respond to 
ectopic NOTCH3 ICD expression with increased growth and viability in vitro (Gupta et al., 2013, McAuliffe 
et al., 2012, Park et al., 2010). These experiments using other cell lines, however, were conducted under 
conditions of chemotherapeutic treatment, differing from the experiments we conducted with ID8 IP2 cells. 
The majority of previous studies linking Notch3 activity to increased growth or reduction of apoptosis were 
conducted in ovarian cancer cell lines expressing high levels of NOTCH3, and used reduced expression or 
inhibition to study the role of NOTCH3 (Hu et al., 2014, Park et al., 2006b). In contrast, we focused on 
ectopic expression to analyze an ovarian cancer cell with low Notch3 signaling. Both approaches have their 
merits. In ID8 IP2 cells, Notch3 signaling did not influence cisplatinum resistance (Figure 4.3). This is also 
contrary to in vitro and in vivo studies previously performed with different cell lines, which suggest Notch3 
signaling promotes resistance to platinum therapy (Groeneweg et al., 2014a, Gupta et al., 2013, McAuliffe 
et al., 2012, Park et al., 2010, Rahman et al., 2012, Shah et al., 2013). One can speculate that the ID8 IP2 
cell line represents an early stage ovarian cancer cell which has not acquired other alterations that may be 
necessary, and Notch3 may not be sufficient to cause these changes. Alternately, the ID8 IP2 cells may 
resemble another subtype of ovarian cancer. 
 The ID8 IP2 cell represented an excellent model for the study of metastatic spread of ovarian 
cancer. The analysis of Notch3 oncogenic function in ID8 IP2 cells uncovered a novel role for Notch as an 
oncogene by potential promotion of early metastasis. This early metastasis was defined by an accelerated 
disease burden/ascites; that is ascites accumulation was more significant at 8 weeks in ID8 IP2 Notch3IC 
bearing mice as compared to Control.  
 One must consider that the lack of an observable effect of Notch3IC on ID8 IP2 growth in vitro may 
stem from excessively high levels of NOTCH3 ICD being potentially toxic to the cells. Since we are using a 
constitutively active form of the NOTCH3 receptor that likely induces super-physiologic levels of Notch 
signaling, the NOTCH3 ICD may be toxic. The observation that cells subjected to FACS for a purer high 
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NOTCH3 ICD expressing population did show a reduction in viability of the Notch3IC cells compared to 
control indicates a possibility of toxicity to this line. It is difficult to know how our ectopic expression of 
NOTCH3 ICD compares to ovarian cancer cells with amplification of NOTCH3, and further examination of 
upregulation of full length NOTCH3 may be warranted. 
 We discovered that NOTCH3 signaling in ID8 IP2 cells leads to a significant increase in 
mortality, defined as endpoint triggered by measured ascites accumulation. The significant survival data 
indicated a role for earlier phase tumorigenesis or metastasis. The Gehan-Breslow-Wilcoxon assessment 
signifies that the risk of death for the Notch3IC mice is higher early on. The data suggest that Notch3 
signaling may contribute to early steps in disease progression, such as adhesion and invasion of cells into 
the peritoneum, rather than later subsequent growth of established metastatic lesions. We therefore wanted 
to further investigate the mechanism of the differences between the Notch3IC compared to Control to 






NOTCH3 ACTIVATION IN ID8 IP2 OVARIAN CANCER CELLS AFFECTS 




After an increase in expression of the Notch3 signaling pathway components was found in ovarian 
cancer by TCGA analysis and other studies, there have only been a few attempts to investigate the 
downstream affected gene signature of NOTCH3 expressing ovarian tumors (Cancer Genome Atlas 
Research, 2011, Lu et al., 2004, Nakayama et al., 2007, Park et al., 2006b). Among a handful of genes 
correlated with NOTCH3 high expressing ovarian cancer lines, Pbx1 has been shown to regulate survival 
of ovarian cancer cells in high NOTCH3 expressing lines (Park et al., 2008). It was also shown Col4a2 is 
upregulated in high NOTCH3 ovarian cancer lines and is associated with anoikis resistance through 
subsequent kinase activation (Brown et al., 2015). Another study found an association with expression of 
cell cycle checkpoint and nucleotide synthesis pathways to a high NOTCH3 expressing human cell line 
(Chen et al., 2012). 
 We wanted to comprehensively determine the downstream targets and pathways affected by 
Notch3 signal activation in the ID8 IP2 luc model to help elucidate the mechanism of NOTCH3 effect on 
ovarian cancer cells. In the previous chapter, we documented an effect on survival of tumor bearing mice 
and wanted to further determine what induced pathways could be the cause of this effect. The effect we 
observed on survival is consistent with studies showing a correlation in humans between poor prognosis 
and reduced survival with increased NOTCH3 expression (Hu et al., 2014, Jung et al., 2010, Liu et al., 
2016, Park et al., 2010). Since NOTCH3 is a transcriptional regulator, we used RNA-Seq analysis of our 
Notch3IC and Control ID8 IP2 luc lines to determine what pathways may be influenced by Notch3 signaling. 






RNA-Seq analysis confirms that NOTCH3 ICD expression activates Notch targets 
 We determined that NOTCH3 signaling activation in ID8 IP2 luc cells reduced tumor-bearing mouse 
survival in vivo, and increased the disease burden of mice at similar time points. In addition, there was 
minimal effect of NOTCH3 on the growth of ovarian cancer cells in vitro. We, therefore, wanted to determine 
what pathways may be responsible for the effect we observed in our ID8 IP2 mouse model.  
 We evaluated the gene profile of the ID8 IP2 luc Notch3IC cells compared to Control by RNA 
sequencing (RNA-Seq) and interrogated the data to determine which pathways were influenced by 
NOTCH3 signaling. We hypothesized that pathways related to metastasis and peritoneal growth may be 
affected because our statistical analysis of the survival data indicating an early tumor phase effect, as well 
as the evidence that the effect was unlikely directly related to proliferation or survival of the cancer cells.  
 We evaluated 4 separate sets of ID8 IP2 luc Notch3IC and matched Control lines by RNA-Seq 
(Sets #1 - #4, previously described in Chapter 4). Briefly, these lines were generated by lentiviral infection 
of the tumorigenic mouse line ID8 IP2 luc with pCCL (Control), or pCCL containing the Notch3 intracellular 
domain (Notch3IC). RNA was isolated from each line, and 30 million sequence reads for each line were 
obtained. Data collected from RNA-Seq was processed in Cufflinks software to generate counts, the 
number of reads for each gene determining expression level. The data was then assessed by DEseq 
software to determine the differential expression between Notch3IC and Control for the average counts per 
gene for repeated samples.  
The generated counts were evaluated for Notch pathway genes in order to confirm that NOTCH3 
ICD expression led to regulation of canonical Notch target genes. We found that the RNA-Seq data 
confirmed the data that we previously observed with RT-qPCR (See Chapter 4, Figure 5.1) for several 
Notch target genes. First, the gene Notch3 was significantly enriched in Notch3IC lines. Several canonical 
Notch downstream targets such as HeyL, Nrarp, Hey1, and Hey2 (adj p = 1.93E-04, adj p = 5.39E-06, adj 
p = 1.24E-05, adj p = 1.84E-04, adj p = 1.29E-04 respectively) were upregulated. The pattern of Notch 
target gene response was similar to the previously generated RT-qPCR data, with upregulation of Hey 
genes but not Hes genes, consistent with NOTCH3 signaling. This data adds to the confidence that 






Figure 5.1 A Notch3 signaling signature is enriched in the RNA-Seq analysis of ID8 IP2 luc Notch3IC 
compared to Control. (A) Heat map showing log2 fold change of each ID8 IP2 luc line compared to the 
log2 fold change for the mean of the Controls. Genes represented are Notch3 pathway and known Notch 
target genes. There is significant upregulation for Notch3 and known downstream targets, demonstrating 
active Notch3 signaling. Stars denote genes also assessed by RT-qPCR shown in B.  (B) RT-qPCR data 
described in Chapter 4 for lentiviral infected Sets #1 - #4 of ID8 IP2 luc. Graph displays fold change for 
Notch3IC compared to Control for each line set. Data show a similar pattern, but greater magnitude, to 
changes observed in RNA-Seq data. See starred genes in A for comparison.    
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Analysis of RNA-Seq data uncovers pathways regulated by NOTCH3 ICD in ID8 IP2 
In order to determine which pathways were altered in the NOTCH3 activated ovarian cancer cells, 
we examined our RNA-Seq data for up- or downregulated genes in Notch3IC lines compared to the Control. 
We chose genes to evaluate further by selecting genes with an adjusted p value < 0.1 and average log2 
fold change ≥ 1 or ≤ -1(Appendix Figures A5.1 and A5.2). This created a list of 478 upregulated genes, and 
a list of 163 downregulated genes. We then subjected each list of genes to pathway analysis to determine 
which cellular pathways were most affected by the expression of the Notch3 intracellular domain.  
 We completed pathway analysis in the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) developed by the National Institute of Allergy and Infectious Diseases at the 
National Institutes of Health. Many pathways were affected, but we chose to focus on the most significantly 
upregulated pathways (Tables 5.1 and 5.2) from the 355 pathways identified as significantly upregulated 
across 4 databases.   
We chose not to focus on enriched pathways determined from the genes significantly 
downregulated with adjusted p < 0.1 and log2 fold change ≤ -1 (appendix Figure A5.2). DAVID pathway 
analysis of downregulated genes produced fewer pathways to assess (76 pathways versus 355 pathways 
for upregulated genes). In addition, fewer genes were identified per pathway where all pathways found to 
be significantly enriched (p<0.5) all contained 10 or fewer of our selected downregulated genes, whereas 
our significantly upregulated pathways showed up to 56 of our selected upregulated genes identified within 
a pathway (data not shown). This is likely because fewer genes were significantly downregulated. This may 
be because the NOTCH3 receptor and its nuclear complex is a transcriptional activator. Of note, we did 
see some downregulation of cell adhesion pathways, described in further detail below, in this set (appendix 







Table 5.1 Most significant pathways by p value for each database sampled by DAVID show many 
pathways related to adhesion and ECM are regulated by active Notch3. This table demonstrates the 
pathways most significantly enriched from analysis of our selected upregulated genes with adjusted p < 0.1 
and log2 fold change of 1 or greater. Pathways related to adhesion or the extracellular matrix are listed in 
red.    
  
Pathway
 Database Pathway Name 
Gene
 Count p Value
Fold
 Enrichment
KEGG mmu04510:Focal adhesion 21 1.65E-08 4.66
KEGG mmu04512:ECM-receptor interaction 14 4.18E-08 7.31
KEGG mmu04151:PI3K-Akt signaling pathway 25 4.51E-07 3.27
KEGG mmu05410:Hypertrophic cardiomyopathy (HCM) 10 4.70E-05 5.82
KEGG mmu05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) 9 1.35E-04 5.82
BIOCARTA m_slrp2Pathway:Function of SLRP in Bone: An Integrated View 3 6.84E-03 21.02
BIOCARTA m_tob1Pathway:Role of Tob in T-cell activation 4 2.99E-02 5.60
BIOCARTA
m_nktPathway:Selective expression of chemokine receptors during 
T-cell polarization 4 7.71E-02 3.87
BIOCARTA m_erythPathway:Erythrocyte Differentiation Pathway 3 9.38E-02 5.60
GO TERM GO:0007155~cell adhesion 43 5.07E-14 3.97
GO TERM GO:0007275~multicellular organism development 56 1.75E-09 2.42
GO TERM GO:0014031~mesenchymal cell development 6 1.09E-07 38.37
GO TERM GO:0001525~angiogenesis 22 1.14E-07 4.09
GO TERM GO:0001568~blood vessel development 12 4.53E-07 7.57
REACTOME Integrin cell surface interactions 12 4.00E-06 5.98
REACTOME ECM proteoglycans 9 5.44E-06 8.85
REACTOME Collagen biosynthesis and modifying enzymes 9 1.60E-04 5.66
REACTOME cGMP effects 5 2.61E-04 14.76




 The pathways with the most significantly enriched genes appearing in our list of upregulated genes 
included pathways related to cell adhesion and the extracellular matrix for 3 of the 4 databases probed by 
DAVID. We were intrigued by this since cell adhesion and migration have obvious implications for tumor 
metastasis. We, therefore, looked at all the pathways significantly enriched for Notch3IC upregulated genes 
that were related to cell adhesion and adhesion to the extracellular matrix (Table 5.2, see appendix Figure 




    
Table 5.2 Notch3 intracellular domain significantly upregulates many significant adhesion and 
extracellular matrix pathways identified by DAVID analysis. The table shows all the significantly 
enriched pathways for upregulated genes that are related to adhesion and the extracellular matrix, arranged 
by significance.  
  
Pathway





GO TERM GO:0007155~cell adhesion 43 5.07E-14 3.97
KEGG mmu04510:Focal adhesion 21 1.65E-08 4.66
KEGG mmu04512:ECM-receptor interaction 14 4.18E-08 7.31
REACTOME Integrin cell surface interactions 12 4.00E-06 5.98
REACTOME ECM proteoglycans 9 5.44E-06 8.85
GO TERM GO:0030199~collagen fibril organization 8 2.15E-05 9.18
REACTOME Collagen biosynthesis and modifying enzymes 9 1.60E-04 5.66
GO TERM GO:0033630~positive regulation of cell adhesion mediated by integrin 5 2.73E-04 14.92
REACTOME  Syndecan interactions 5 4.78E-04 12.79
GO TERM GO:0030198~extracellular matrix organization 10 1.02E-03 3.93
REACTOME Molecules associated with elastic fibres 6 1.68E-03 6.77
GO TERM GO:0007160~cell-matrix adhesion 8 1.89E-03 4.53
REACTOME A tetrasaccharide linker sequence is required for GAG synthesis 5 3.10E-03 7.99
GO TERM GO:0006024~glycosaminoglycan biosynthetic process 5 3.26E-03 7.99
GO TERM GO:0033627~cell adhesion mediated by integrin 4 4.10E-03 11.94
REACTOME  Collagen degradation 7 8.11E-03 3.95
REACTOME Assembly of collagen fibrils and other multimeric structures 6 1.08E-02 4.43
GO TERM GO:0030155~regulation of cell adhesion 5 1.40E-02 5.33
GO TERM GO:0007229~integrin-mediated signaling pathway 7 1.77E-02 3.37
REACTOME  Laminin interactions 4 3.49E-02 5.48
REACTOME NCAM1 interactions 4 3.49E-02 5.48




 We wanted to more closely examine the gene signature in these adhesion and ECM pathways to 
identify candidates that could affect metastasis. We decided to focus on collagen and integrin genes 
because these gene are critical in attachment of ovarian tumor cells to the peritoneum and the signaling 
involved in subsequent formation of metastatic lesions (Shen et al., 2012, Lengyel, 2010). Collagens and 
integrins were also upregulated genes from our RNA-Seq data that were frequent components of the 
pathways identified as significantly enriched (appendix Figure A5.3). Several collagen genes, Col3a1, 
Col5a3, Col6a2, Col8a1, Col14a1, Col15a1, and Col18a1 were significantly upregulated (adj p = 1.51E-02, 
9.85E-03, 3.76E-02, 2.30E-02, 3.16E-09, and 4.12E-04 respectively) (Figure 5.2). Significantly upregulated 
integrin genes include Itga1, Itga7, Itga9, Itga11, Itgb3, and Itgb5 (adj p = 7.70E-03, 2.30E-02, 5.80E-06, 




Figure 5.2 Expression of collagen genes for all samples subjected to RNA-Seq show a subset of 
enriched collagen genes induced by Notch3 intracellular domain. The heat map displays the log2 
fold change in ID8 IP2 luc Notch3IC and Control lines for each collagen gene compared to the mean log2 
fold expression of the Controls for each gene. Genes with an asterisk have adjusted p value less than 0.1 






Figure 5.3 Integrin receptor genes expression for all samples assessed by RNA-Seq show a set of 
enriched integrin genes induced by Notch3 intracellular domain activity. This heat map displays the 
log2 fold change in ID8 IP2 luc Notch3IC and Control lines for each collagen gene compared to the mean 
log2 fold expression of the Controls for each gene. Genes with an asterisk have adjusted p value less than 
0.1 and average log2 fold change greater than 1, or less than -1 for the average Notch3IC fold change 




 We sought to confirm pathway results generated in DAVID by completing a separate pathway 
analysis on our RNA-Seq results. We converted the selected genes to human orthologues and assessed 
the data with the Gene Set Enrichment Analysis (GSEA) database developed by the Broad Institute. This 
analysis was completed on the log2 fold change of all genes assessed by RNA-Seq and processed through 
DEseq. Unlike the DAVID analysis, which simply assesses whether there is a connection between genes 
entered into the analysis, GSEA takes into account the magnitude of each log2 fold change value and the 
weight each individual gene has in a given pathway comparison. In addition to other pathways, we did see 
significant enrichment for adhesion and extracellular matrix pathways concurrent with DAVID results (Table 
5.3). Again, we saw multiple pathways related specifically to collagen and integrin genes (Table 5.3, Table 
5.4) Other significantly enriched pathways can be viewed in appendix Table A5.4. We also saw significant 
enrichment of downregulated pathways related to adhesion, most of which were related to cell to cell 







Table 5.3 Adhesion and extracellular matrix pathways are significantly enriched in Notch3IC cells 
when analyzed by GSEA pathway analysis. This table displays the pathways that were determined to be 
upregulated by analysis with GSEA comparison to pathway databases when assessing all gene expression 










NABA_COLLAGENS 29 2.37E-03 1.73
REACTOME_COLLAGEN_FORMATION 30 1.83E-02 1.66
PID_INTEGRIN1_PATHWAY 42 1.73E-02 1.62
ONDER_CDH1_TARGETS_2_UP 69 1.61E-02 1.61
NABA_BASEMENT_MEMBRANES 24 3.14E-02 1.58
PID_INTEGRIN_CS_PATHWAY 16 4.95E-02 1.54




Figure 5.4 GSEA data analysis of Notch3IC compared to Control data shows collagen genes among 
the top 20 enriched pathways, and as the most significantly enriched of the adhesion and 
extracellular matrix pathways. This figure displays the core enrichment genes from the 
NABA_COLLAGENS pathway which was significantly enriched by GSEA analysis (NOM p = 0.002366864). 
Genes with a standard deviation less than 0.5 with small variance were removed from this list. To view all 






We determined Notch3 pathway activation led to a reduction in survival of mice implanted with 
tumor cells in vivo, but saw little evidence in vitro for an effect of NOTCH3 on growth properties of cells, 
and no significantly increased tumor burden at time sacrifice relative to control tumor cells. We therefore 
chose to further investigate the cause of increased tumor lethality with Notch3IC expression. We evaluated 
the gene signature of Notch3IC and Control ID8 IP2 luc ovarian cancer lines by RNA-Seq and analysis of 
the genes and pathways produced. We found through this analysis that adhesion and extracellular matrix 
pathways were significantly enriched in Notch3IC ID8 IP2 luc compared to Control. Upregulated pathways 
showed a pattern of collagen and integrin gene involvement.  
For enriched pathways containing downregulated genes, only the GO Consortium database 
returned any pathways connected to adhesion in DAVID analysis. These pathways appear to be mostly 
involved in cell to cell interactions rather than cell to matrix interactions emphasized in the upregulated data 
(see Appendix Table A5.2). GSEA analysis returned similar results in relation to enriched pathways 
identified with downregulated adhesion genes (Appendix A5.5). This upregulation of adhesion of and 
extracellular matrix pathways, but downregulation of cell to cell adhesions may be consistent with the idea 
that metastasis of tumor cells need both to be able to detach from each other or the ovary/ fallopian tube, 
to be mobile, but also attach to the peritoneal ECM to seed metastatic lesions. Downregulated genes related 
to ECM attachment may also represent fine tuning in the cancer cells to specifically attach to particular 
peritoneal ECM, which is rich in collagen I. This can be assessed by reviewing which collagens and integrin 
receptor components show a greater log2 fold change in the heat maps for each class of gene (Figures 5.2 
and 5.3, Figure A5.3). For example, Itga3, which generally binds laminin, is significantly downregulated, 
while Itga1, which binds collagen I, is upregulated (Hynes, 2002, Witz et al., 2001).   
Based on these consistent results found from both pathway analyses in the enhancement of 
adhesion and ECM pathways, we hypothesized that Notch3 signaling activation affects the adhesion or 
migratory properties of ID8 IP2 ovarian cancer cells. In the following chapter, we explored if activation of 
Notch3 generates a specific phenotype related to adhesion on extracellular matrix in the ovarian cancer 
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ID8 IP2 model.  Upregulated adhesion and ECM genes may explain reduced survival in the context of 
enhancing the ability of metastatic tumor seeds to adhere to the peritoneum.  
CHAPTER 6 
 
ACTIVE NOTCH3 SIGNALING EFFECTS ADHESION TO COLLAGENS IN 




Our previous data showed an enrichment for gene expression of proteins involved in adhesion and 
extracellular matrix, as identified by pathway analysis. We also determined that Notch3 signaling in ovarian 
cancer cells was associated with a reduction in survival and accelerated disease development. We 
therefore wanted to explore the role of adhesion to the peritoneal extracellular matrix (ECM) as a potential 
factor in Notch3-driven ovarian tumor progression. 
 In ovarian cancer, adhesion represents an important part of disease development. Adhesion 
characteristics are critical to the attachment of tumor cells to the ECM of peritoneal organs and wall, which 
are the sites of metastasis in ovarian cancer. These metastases are what characterize late stage disease, 
often already present at the time of diagnosis. Adhesion to the peritoneum promotes cell viability by allowing 
tumor cells to evade anoikis and lymphatic clearance, which can occur while detached in the peritoneum 
(Sodek et al., 2012).  
Adhesion of metastases occurs as tumor cells or spheroids of tumor cells attach to the ECM in a 
metastatic site via cell surface receptors. The most common sites of peritoneal metastasis, in order of 
preference for tumor cell attachment, are the contralateral fallopian tube and ovary, followed by the 
omentum, right diaphragm, and mesentery of the small intestine (Lengyel, 2010). Collagens I and IV, 
laminin, and fibronectin are the most abundant components in the peritoneal lining and omental ECM,  
(Lengyel, 2010). The matrix composition of peritoneal ECM is rich in collagen I, which is also the most 
diffuse and widespread matrix component around the mesothelium, the cells which compose the surface 
of the peritoneum (Witz et al., 2001). Collagen I is high in preferentially adhered omental locations. It has 
been shown ovarian cancer cells preferentially bind to collagen I over other ECM components.  (Sorensen 
et al., 2009, Moser et al., 1996). The cellular receptors that bind ECM include integrins, which are essential 
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to the attachment of ovarian cancer cells to ECM (Lengyel, 2010, Moser et al., 1996, Sodek et al., 2012). 
Not only is the establishment of metastatic sites through tumor cell binding dependent on collagens, but 
ovarian tumor cells bound to fibrillar collagen I via integrin receptors engage in cell signal regulation, which 
better enable migration and invasion, the subsequent steps of metastasis (Shen et al., 2012).  
ECM and integrin signaling is important to non-adhered cells and ECM and integrins assist in the 
formation of spheroids.  As ovarian cancer cells must survive in the peritoneal fluid or ascites in order to 
travel to metastatic sites, there are mechanisms to resist anoikis and other apoptotic signals (Sodek et al., 
2012). Collagen-integrin signaling contributes to cancer cell survival after detachment of cancer cells and 
spheroids from the tumor (Symowicz et al., 2007, Lengyel, 2010). Formation of spheroids assists in cell 
survival; integrin presence in spheroids contributes to survival signaling in cancer cells that assists in 
surviving while detached, as well as chemotherapy resistance (Sodek et al., 2012). ECM components 
collagens, laminin, and fibronectin are present in ascites (Lengyel, 2010), which may help in producing 
survival signals for cells until they reach a peritoneal metastatic site. Collagen expression in ovarian cancer 
patient samples has been associated with poor patient survival; a gene signature was identified related to 
poor overall survival in HGSC patients, including COL11A1, COL5A2, and COL6A2 (Cheon et al., 2014). 
COL11A1 knockdown in implanted cell lines was also linked to reduced tumor progression in mice (Cheon 
et al., 2014).   
Previous work by Brown and colleagues (2015) has demonstrated a link between Notch3 and 
induction of collagen in ovarian cancer cells, and the importance of this induction to ovarian cancer cell 
survival. Increased Notch3 levels were connected to significantly increased levels of Col4α2 in ovarian 
cancer cells. Furthermore, culture with collagen IV led to an increase in cell viability in Notch3 siRNA 
knockdown cells. Col4α2 was found to be necessary for survival of ovarian cancer cells, as direct 
knockdown of Col4α2 led to a reduction in viable cells which is rescued by growth on collagen IV (Brown 
et al., 2015). The RNA-Seq data we generated showed a significant enrichment in expression of collagen 
pathway genes and collagen-binding integrin genes (see Chapter 5, Figure 6.1). While Col4α2 was not 
significantly upregulated in the RNA-Seq data we generated, there was an increase in Col4α2 in our data 
with introduction of Notch3 intracellular domain (DEseq baseMean Control 6520.7, baseMean Notch3IC 
17086.5 with a log2 fold increase of 1.4 p = 0.009, adj p = 0.148). Col4α2 was labeled as a core enrichment 
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gene in GSEA analysis compared to the NABA_COLLAGENS significantly upregulated pathway (Chapter 
5). We thus hypothesized that Notch3 may influence the ability of ID8 IP2 luc cells to survive during 
metastasis during growth in the peritoneum. This state may be promoted by interaction with collagen in the 
extracellular matrix of metastatic sites.  
In summary, the RNA-Seq data comparing ID8 IP2 luc Notch3IC and Control suggested a role for 
adhesion and ECM interactions in connection with high Notch3 expression, which indicates that adhesion 
may be a mechanism for increased tumor aggressiveness linked to Notch3. Based on the known roles of 
adhesion and extracellular matrix in ovarian cancer metastasis and the results of RNA-Seq analysis 
demonstrating upregulated adhesion and extracellular matrix genes, we wanted to further investigate the 
adhesive properties of ovarian cancer cells with Notch3 signal activation. We hypothesized that an increase 
in adhesive ability to extracellular matrix in NOTCH3 intracellular domain overexpressing ovarian cancer 






Figure 6.1 Integrin receptor components altered in Notch3IC compared to Control determined by 
RNA-Seq. This figure displays a subset of mammalian integrin receptor family proteins that create αβ 
integrin heterodimer receptors. Each α subunit is shown with its corresponding receptor category and has 
a line connecting to its associated β dimerization partners. Receptor components with red circles are 
upregulated in our RNA-Seq data, and the green circle represents downregulation. Gray circles represent 
genes that displayed low expression in both Notch3IC and Control lines. Low expression was defined as a 
DEseq baseMean below 10 transcripts for the averages of both lines. LDV are leucine-aspartate-valine 
containing ECM components such as fibronectin, (Hynes, 1992, Humphries et al., 2006). RGD is an 
arginine-glycine-aspartate motif found in ECM components like fibronectin and vitronectin (Hynes, 2002).  





ITGA1 cell surface expression is increased with Notch3 signal activation 
 RNA-Seq data indicated a role for Notch3 signaling in adhesion and extracellular matrix pathways 
with strongest significance in the pathways involving collagens and integrins (See Chapter 5, Figure 6.1). 
We wanted to delve deeper into the role of these genes in the ID8 IP2 ovarian cancer model. Based on the 
adhesion and extracellular matrix pathways identified by RNA-Seq, we sought to confirm whether 
upregulated mRNAs resulted in increased expression levels of adhesion proteins on the cell surface of 
Notch3IC activated tumor cells compared to Control.  
We specifically chose to examine ITGΑ1, a collagen receptor component significantly upregulated 
in the RNA-Seq assessment (log2 fold change 3.8, adj p = 0.00770), highlighted in Figure 6.1. ITGA1 
dimerizes with ITGB1 in order to bind collagens; this dimer pair binds collagens I, IV, VI, and fibrillary 
collagens (Leitinger and Hohenester, 2007). As previously mentioned, the peritoneal ECM is rich in 
collagens I and IV, and ovarian cancer cells preferentially bind collagen I (Lengyel, 2010). The level of 
ITGB1 did not change significantly in Notch3IC cells, but was found at high levels in both Control and 
Notch3IC (DEseq baseMean Control 17,913.9, baseMean Notch3IC 19,414.9), suggesting abundant 
availability for dimerization with ITGA1. In order to analyze cell surface expression of ITGA1, we stained 3 
sets of Notch3IC and control cell lines with antibodies against ITGA1 and subjected them to flow cytometry 
in two duplicate experiments. We observed an increase in the percent of ITGΑ1 positive cells in Notch3IC 
compared to Control, confirming our RNA-Seq analysis (p = 0.0414, Welch’s t-test) (Figure 6.2).  
 We attempted to determine if there was a similar increase in surface ITGΑ11, the other collagen 
receptor gene identified as significantly upregulated in our RNA-Seq data (log2 fold change 3.4, adj p = 
1.32E-06) in Notch3IC compared to Control. However, the only antibody available to recognize mouse 




Figure 6.2 Notch3IC display increased surface levels of ITGΑ1 by flow cytometry.  
(A) The left panel shows an example of the gate used to determine live cells for each population. It shows 
forward and side scatter area for an ID8 IP2 luc only sample. The center panel shows the live cells of ID8 
IP2 luc plotted for GFP (an indicator of NOTCH3 expression, as discussed in chapter 4) and AF647-
conjugated anti-ITGA1. This demonstrates an unstained Control population that should be negative for both 
NOTCH3 and ITGA1. The right panel displays isotype control staining of live gated Notch3IC cells that are 
positive for NOTCH3, and is set to minimize background signal for ITGA1. (B) The left panel shows an 
example of a Control population of cells, while the right panel shows a Notch3IC cell line. NOTCH3-
expressing cells were determined by GFP positive signal, and ITGA1 positive cells were determined by 
AF647 positivity. As is demonstrated in the figure, the NOTCH3 positive cell population contains a shift 
toward ITGA1 positive cells (Q2). (C) The left graph demonstrates the significant increase in the percent of 
cells with ITGA1 surface expression in Notch3IC compared to Control measured by the percent of AF647 
positive cells in each live population (p = 0.0414, Welch’s t-test). The right graph displays the distribution 




Notch3 signaling leads to an increase in adhesion of ID8 IP2 cells to collagens  
 Based on the RNA-Seq upregulation of extracellular matrix ligand and receptor genes, as well as 
the confirmed expression of surface integrin α1, we sought to determine if different extracellular matrices 
known to be in the peritoneum interacted differentially with Control and Notch3IC activated tumor cells. We 
assessed the ability of Notch3IC and Control cell lines to attach to five different extracellular matrices in 
vitro; we investigated interaction with fibronectin, laminin, vitronectin, collagen I, and collagen IV (Lengyel, 
2010, Witz et al., 2001). We added equal numbers of Notch3IC or Control cells to plates coated with an 
ECM component, allowed the cells to settle and attach for a specified period of time, and determined the 
number of cells which had successfully attached to the ECM. It was found that all ID8 IP2 cells bound well 
to vitronectin and fibronectin coated plates, and NOTCH3 ICD expression did not further enhance 
attachment (Figure 6.3, Figure A6.1). All ID8 IP2 luc cells bound more poorly to collagens and laminin 
coated dishes than to fibronectin and vitronectin, adhering at lower numbers over the same period of time 
with equal numbers of cells (Figure A6.1, data not shown). Notch3IC activated tumor cells, however, were 
able to better adhere to collagens than Control, while binding equally well to the other matrices (Figure 6.3). 
There was a significant increase in the proportion of Notch3IC cells compared to Control adhering to both 
collagen I (p = 0.0118, Welch’s t-test) and collagen IV (p = 0.0163, Welch’s t-test). 
We evaluated whether specifically blocking ITGA1 binding would reverse the observed increase in 
collagen I or collagen IV binding of Notch3IC cells. We used a putative mouse ITGΑ1 blocking antibody as 
outlined in published experiments (Gotwals et al., 1996, Mendrick et al., 1995, Miyake et al., 1994). We 
expected that blocking ITGA1 may inhibit the increased capacity of Notch3IC cells to adhere to collagens. 
It was found, however, that the number of Notch3IC cells Compared to control was not significantly different 
between treatment of cells with ITGΑ1 antibody compared to isotype control antibody for either collagen I 
(p =0.5616, Welch’s t-test) or collagen IV (p =0.6888, Welch’s t-test) (Appendix Figure A6.2).  There may 
be several reasons why ITGA1 antibody blocking was not observed to reduce the attachment of Notch3IC 
active cells to collagen extracellular matrix. This result could be due to the increased presence of ITGA11 
dimerizing with ITGB1 and attaching to collagens. In addition, the antibody to ITGA1 may not be providing 





Figure 6.3 ID8 IP2 luc Notch3IC more adherent to collagens than Control. (A) The graph shows the 
proportion of adhered Notch3IC cells compared to adhered Control cells for each extracellular matrix 
examined. The line at 1 therefore represents the Control compared to itself for each matrix. Notch3IC 
display a significant increase in the number of cells adhering to collagen I (p = 0.0118) and collagen IV (p 
= 0.0136, Welch’s t-test). There is no significant difference in adhesion to laminin, fibronectin, or vitronectin 
for Notch3IC and Control (p = 0.0474, p = 0.6237, p = 0.3075, Welch’s t-test). There is no significant 
difference in adhesion to tissue culture plates without extracellular matrix coating (p = 0.4206, Welch’s t-
test). (B) Representative images of ID8 IP2 luc cells on collagen I fixed, stained, and imaged with a Celígo 
instrument for adhesion experiments. Scale bar represents 200μm.
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Notch3 signaling causes reduced migration of ID8 IP2 on extracellular matrix proteins 
 
The discovery that Notch3IC tumor cells adhere better to collagens suggested that we further 
explore the interaction of Notch3IC cells with collagen extracellular matrix. As previously mentioned, once 
adhered to collagen I, ovarian cancer cells can engage in signaling that allows tumor cells to better 
participate in the next steps of peritoneal metastasis such as migration and invasion (Shen et al., 2012). 
We endeavored to investigate the effect of Notch3IC signaling levels in ovarian tumor cells on migration 
over collagen I coated surfaces. We proposed that cells might be able to migrate better along collagen I 
based on its increased ability to adhere to collagen I.  
 We investigated migration on collagen by assessing the ability of cells to fill in a cell-free gap (a 
“wound”) on collagen-coated plates. A confluent monolayer was seeded and grown on collagen I-coated 
plates around a plug; a wound was created by removal of the plug covering part of the plate, and then the 
percent area of the wound covered by cells was measured over time. We assessed 2 experiments of 
quadruplicates for 3 ID8 IP2 luc line sets and examined the average for each set. Surprisingly, Notch3IC 
cells seeded on collagen I displayed a significant reduction in capacity to migrate across collagen I and fill 
the wound. Notch3IC cells were shown to migrate significantly more slowly across collagen I at both 6 and 
12 hours (p = 0.0432, p = 0.0181, Welch’s t-test).  
Migration in the absence of extracellular matrix was assessed similarly, with a wound created by 
scratching a pipette tip across a confluent monolayer on an uncoated tissue culture plate. It was determined 
there was no significant difference in the ability of cells to close a wound created by a scratch in a confluent 
monolayer at several time points post formation of the scratch/wound (p = 0.4142, p = 0.5422, p = 0.4133, 
p= 0.9637 for 3, 6, 9, and 12 hours respectively, Welch’s t-test).  
We wanted to determine if the effect on Notch3IC migration observed on collagen I was unique to 
collagen, or similar to behavior on another extracellular matrix. We repeated the migration assay performed 
previously over collagen I with fibronectin, seeding cells around a wound area on fibronectin coated plates. 
Notch3IC migration on fibronectin also displayed a significant reduction in migration compared to Control 
at both 6 and 12 hours (p = 0.0004, p = 0.0020, Welch’s t-test).  Thus, we posit that changes in migration 
due to Notch3 signal activation are not matrix specificity but possibly a general feature of the migration 




Figure 6.4 Active Notch3 causes reduced migration of ID8 IP2 luciferase on extracellular matrix.  
(A) Migration of ID8 IP2 luc Notch3IC cells is significantly reduced on collagen I at both 6 hours and 12 
hours (p = 0.0432, p = 0.0181, Welch’s t-test). The graph displays area of cells migrated into the open area 
at time 0. (B) Migration of ID8 IP2 luc Notch3IC is significantly reduced on fibronectin at both 6 and 12 
hours (p = 0.0004, p = 0.0020 Welch’s t-test). The graph displays area of cells migrated into the open area 
from time 0. (C) There is no significant difference in migration without extracellular matrix into a scratch 
wound (p = 0.4142, p = 0.5422, p = 0.4133, p= 0.9637 for 3, 6, 9, and 12 hours respectively, Welch’s t-
test). The graph shows area remaining open in the scratch (not yet covered in migrated cells) compared to 
the area open at the time of scratch generation.  
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Notch3 signal activation does not alter in vitro invasion properties of ID8 IP2 cells 
 In light of the findings demonstrating that adhesion to and migration over extracellular matrix are 
altered between Notch3IC and Control cells, we explored whether an effect on invasion through 
extracellular matrix would be observed as well. We investigated the ability of Notch3IC lines to invade 
through collagen I compared to Control. We measured invasive capacity by the amount of cell migration 
through a Boyden chamber pre-coated with collagen I. This assay requires that the cells not only migrate 
through a porous membrane to the other side of a trans-well insert (designed with space between the 
membrane and bottom of the well), but invade through the extracellular matrix coating to do so (Albini et 
al., 1987). We quantified the number of cells able to pass through the matrix and to the other side of the 
membrane. There was no significant difference in invasion observed across the chamber insert (p = 0.5634, 
Welch’s t-test). The same was observed for invasion through Matrigel® GFR (growth factor reduced). 
Matrigel is an amalgam of ECM largely containing laminin, collagen IV, and proteoglycans, along with a 
number of other components derived from murine tumors (Englebreth-Holm-Swarm tumor) (Hughes et al., 
2010, Kleinman and Martin, 2005). The number of cells invading through the Matrigel® GFR (p = 0.8634, 
Welch’s t-test), and the percent invasion through Matrigel® GFR compared to migration through the 
chamber alone (p = 0.6076) were both not significantly different between Notch3IC and Control lines. In 
addition, there was no change in migration through chambers without extracellular matrix between 
Notch3IC and Control lines either (p = 0.1205, Welch’s t-test) based on the number of cells on the bottom 





Figure 6.5 There is no significant change in adhesion with Notch3 activation in ID8 IP2 luciferase 
cells. (A) Invasion through Matrigel GFR coated chamber inserts shows no difference between Control and 
Notch3IC. The left panel displays the percent invasion through Matrigel GFR compared to migration across 
the chamber membrane without extracellular matrix (p = 0.6076, Welch’s t-test). The right panel shows the 
direct cell count for Control and Notch3IC cells invaded through Matrigel GFR (p = 0.8634, Welch’s t-test). 
(B) There is no change in invasion through collagen I with Notch3 signal activation (p = 0.5634). Graph 
displays the 560nm absorbance generated by dye extracted from cells invaded through, and attached to 
the bottom of chambers coated with collagen I. (C) There is no change in migration across the chamber 
insert membrane without extracellular matrix (p = 0.1205, Welch’s t-test). Data was collected from non-
coated chambers assessed along with Matrigel GFR invasion. Graph displays the number of cells crossing 





RNA-Seq data indicated an enrichment for adhesion and extracellular matrix genes with induction 
of Notch signaling induced by the expression of the NOTCH3 intracellular domain. Two classes of ECM 
related proteins highlighted in our analysis were collagen and integrin genes. We show that Notch3 
signaling induces increased collagen binding of ID8 IP2 Notch3IC ovarian cancer cells over Control. 
Focusing on ITGA1, we found that NOTCH3 induced higher levels of ITGA1 on the surface of ID8 IP2, 
possibly causing increased binding to collagens. Tumor cells with active NOTCH3, therefore, may have 
increased ability to interact with collagens in the peritoneum, promoting their attachment and the formation 
of metastatic seeds. These results suggest that the influence of NOTCH3 is specific to the attachment of 
cancer cells to extracellular matrix, and not subsequent steps of metastasis formation, since adhesion was 
increased, but migration was reduced and invasion was unaffected. Since the Notch3IC tumor cells adhere 
better to collagens, they may not be able to migrate as well along the collagen since they are firmly adhered. 
This would indicate the role of NOTCH3 may increase adherence to new metastatic sites as opposed to 
directly assisting the spread across the peritoneum once cells are attached.   
We did not, however, asses for the ability of cells to survive prior to attachment to extracellular matrix in 
vivo or in in vitro assays that may simulate this earlier stage of metastasis. Based on the other known role 
for extracellular matrix and adhesion molecules in anoikis resistance previously discussed, there may also 
be a role for NOTCH3 in maintaining survival of cells in the peritoneum to reach metastatic sites. We have 
shown there is a potential role for Notch3 signaling in the attachment to metastatic sites by demonstrating 
an increased ability to attach to collagens, especially collagen I the most abundant extracellular matrix in 
the surface of the peritoneum. We may, however, want to further investigate in the future if NOTCH3 
expression in our model yields similar results to Brown et al in anoikis resistance, or in the maintenance of 







A model for the effect of Notch3 on metastatic adhesion in ovarian cancer    
 The process of metastasis in ovarian cancer begins with the detachment of ovarian cancer cells 
and/or spheroids from the primary tumor (Lengyel, 2010, White et al., 2014). Tumor cells are then 
distributed throughout the peritoneum in the peritoneal fluid or ascites (Kenny et al., 2011, White et al., 
2014). Ovarian cancer cells have also been demonstrated to have the ability to spread hematogenously, 
through the blood circulation (Pradeep et al., 2014). However, ovarian tumor cells are more likely to form 
metastases when they are spread within the peritoneum, and even hematogenous tumor cells preferentially 
form metastases in the omentum and infrequently form metastases outside the peritoneum (Pradeep et al., 
2014, Gerber et al., 2006, Tarin et al., 1984). Furthermore, patients succumb to peritoneal disease burden, 
and not distant metastases when they do occur (Tarin et al., 1984). In order to achieve dangerous 
metastatic spread, tumor cells must survive in the peritoneal fluid long enough to reach a metastatic site in 
the peritoneal lining, evade anoikis (apoptosis due to loss of anchorage signals) and lymphatic clearance 
(Sodek et al., 2012). Tumor cells acquire anoikis resistance by forming spheroids and by eventual 
attachment to the peritoneum. Spheroids of cancer cells have been shown to escape this type of apoptosis 
by mutual integrin/ECM signaling, cadherin signaling, and VEGF-A/VEGFR2 signaling (Lengyel, 2010, Sher 
et al., 2009, Sodek et al., 2012). Spheroids also enhance chemotherapy resistance by reduced proliferation, 
increased integrin signaling, upregulation of chemotherapy resistance genes, and shielding cells inside 
spheroids from exposure to chemotherapy (Lengyel, 2010, Sodek et al., 2012).   
Attachment of tumor cells to the peritoneal surface to form metastases is a critical step that follows 
release from the primary site and survival in the peritoneum. The peritoneal cavity consists of the pelvic 
and abdominal spaces including all the organs within. The peritoneal lining covers all the tissues within the 
peritoneum including the pelvis, cavity wall, and all organs (Sodek et al., 2012). The surface of the 
peritoneum is comprised of a single confluent layer of mesothelial cells on top of a layer of extracellular 
matrices with sparse fibroblasts and macrophages beneath (Kenny et al., 2009, Lengyel, 2010). Ovarian 
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cancer cells preferentially bind to the surface of the contralateral ovary, the omentum, the right diaphragm, 
and mesentery of the small intestine when seeding metastases (Lengyel, 2010).  
The mesothelial cells in the peritoneal lining normally secrete glycosaminoglycans, surfactant, and 
proteoglycans that prevent fusion or adhesion between the peritoneal organs and may form a poor 
attachment point for tumor cells (Sodek et al., 2012). However, the composition of the ECM under the 
mesothelium includes collagens I and IV, fibronectin, laminin, and vitronectin, where collagen I is the most 
abundant (Kenny et al., 2009, Lengyel, 2010, Witz et al., 2001). It has been shown that ovarian cancer cells 
preferentially adhere to the extracellular matrix versus mesothelial cells, and that mesothelial cells 
themselves can be inhibitory to tumor cell attachment (Niedbala et al., 1985, Kenny et al., 2011, Kenny et 
al., 2007, Ksiazek et al., 2009) (Figure 7.1). 
The omentum is seeded by many ovarian tumors due to its unique environment. The omentum is 
attached to the greater curvature of the stomach and is comprised largely of fat layers and immune 
aggregates, but contains the same surface lining of mesothelial cells and ECM as the rest of the peritoneum 
(Gerber et al., 2006). Tumor cells preferentially bind to the areas containing immune aggregates, which 
provide exposed extracellular matrix, particularly collagen I, and areas that are highly vascularized with 
both blood and lymph vessels (Gerber et al., 2006, Sodek et al., 2012). The area surrounding immune 
aggregates has been shown to be high in mesothelial VEGF-A and comprises a natural environment of 
constitutive angiogenesis that is easily co-opted by tumor cells (Gerber et al., 2006, Sorensen et al., 2009). 
Omental immune aggregates also contain pro-inflammatory cytokines and chemokines (Gerber et al., 
2006).  
In the normal peritoneal environment, there are areas of exposed extracellular matrix at mesothelial 
intercellular junctions and in the omentum at immune aggregates (Sodek et al., 2012). As cancer 
progresses, further damage to the mesothelium allows for increased exposure of the ECM and therefore 
provides more chance of attachment for tumor cells (Sodek et al., 2012, Niedbala et al., 1985). Tumor cells 
preferentially attach to these areas of damage and exposed ECM (Niedbala et al., 1985, Sodek et al., 2012). 
Mesothelial cells are damaged or signaled to retract after interaction with spheroid integrin and inflammatory 




Within ECM, ovarian cancer cells show a preference for binding collagen I over other matrices, and 
spheroids show a preference for collagen I and fibronectin binding (Kenny et al., 2009). Collagen I is 
particularly exposed between mesothelial cell junctions at lymphatic portal areas that occur frequently in 
the omental immune aggregates and in the diaphragm, where ovarian cancer cells show preferential 
binding (Sodek et al., 2012); these areas have larger gaps between mesothelial cells due to pro-
inflammatory cytokine signaling which signals the mesothelial cells to contract/retract (Sodek et al., 2012) 
(Figure 7.1). The tumor cells can then secrete factors that remodel the ECM at attached locations furthering 
metastasis (Niedbala et al., 1985). The fibroblasts present produce ECM and assist with regulation of the 
pro-invasive signals in the ECM (Kenny et al., 2009). Once attached to collagen I, additional invasive 
behavior ensues; tumors are activated to migrate and proliferate, which is enhanced the denser the collagen 







Figure 7.1 Attachment of ovarian cancer cells to the ECM of the peritoneum. 
Ovarian cancer cells adhere to the collagen rich ECM underlying the mesothelium of the peritoneal lining 
of the wall and organs. Extracellular matrix is exposed between gaps in the mesothelium. These gaps occur 
more frequently at areas of higher lymph vascularization and at immune deposits in normal tissue. As 






Based on the process of adhesion to the peritoneal lining by ovarian cancer metastases, we 
propose a model explaining the ability of NOTCH3 expressing ovarian cancer cells to better engage in the 
early steps of metastasis. Our studies have shown an increase in the expression of extracellular matrix and 
adhesion genes, predominantly integrins and collagens, with the activation of Notch3 signaling in ID8 IP2 
cells. We have demonstrated upregulation of integrin α1, which can cooperatively bind collagen I, on the 
surface of Notch3IC cells. We observed an increased affinity of ID8 IP2 Notch3 activated cells for adhesion 
to collagens I and IV in vitro. Our data indicate that Notch3 signaling in tumor cells is correlated with a 
reduction in survival in vivo. Given our results, we hypothesize that the increased ability to adhere collagens 
by integrin receptor expression effects the attachment of ovarian cancer cells to the peritoneum during 
metastasis (Figure 7.2). Peritoneal sites most likely to be chosen for metastasis, as described in the 
literature, are those with exposed collagen I, consistent with our hypothesis. 
Integrin signaling from tumor cells in spheroids has been implicated in the ability to expose 
additional sites of extracellular matrix between the mesothelium for tumor cell adhesion; this may mean that 
in addition to increasing adhesion to collagens in the ECM, which we have shown in this study, there may 
be a further role for upregulated integrin expression in exposing the ECM for attachment. This role of 





Figure 7.2 Proposed model of the influence of Notch3 on ovarian cancer cell metastatic attachment 
to the peritoneum. This model examines the process of adhesion to the peritoneum of already detached 
tumor cells. Tumor cells preferentially adhere to areas where ECM, particularly collagen I, is exposed. As 
cancer progresses, the area of exposed ECM will increase as mesothelial cells are damaged or retract. 
The induction of Notch3 signaling in ovarian cancer cells upregulates integrin receptors able to bind 
collagens in the ECM, and increases the likelihood that tumor cells will be able to attach to these exposed 





Future directions: further investigation of the Notch3 pathway in ovarian cancer metastasis   
 The investigations described here used the ID8 IP2 model, which is derived from mouse ovarian 
surface epithelium, but HGSC may derive from ovarian surface epithelium, fallopian epithelium, or ectopic 
endosalpingiosis (Chapter 1). The results observed in ID8 IP2 may be explored in a fallopian derived line 
to show that Notch3 affects adhesion and extracellular matrix pathways in ovarian cancer cells of multiple 
organs of origin. Our lab has acquired mouse oviduct surface epithelial derived lines from the Dr. Joanna 
Burdette lab at the University of Illinois at Chicago (Endsley et al., 2015, Eddie et al., 2015). We have 
evaluated mouse oviductal lines (MOE) for the presence of NOTCH3 and found that the MOE PTENshRNA 
and MOE PTENshRNA/p53R273H lines expressed little to no observable NOTCH3 ICD on western blot (Figure 
7.3). We have since lentivirally infected the MOE PTENshRNA/p53R273H line with Notch3 intracellular domain 
generating a MOE PTENshRNA/p53R273H/Notch3IC line and a PTENshRNA/p53R273H/Control line. These lines 
were infected in a similar manner with same constructs as the ID8 IP2 luciferase line. On flow cytometry, 
Notch3IC infected lines were found to be GFP positive indicating successful infection (data not shown). 
These lines can therefore be tested to see if Notch3 signaling will show a similar effect on adhesion to 
collagens in vitro that we see in ID8 IP2. We also have human fallopian derived tumorigenic lines from the 
Dr. Ronny Drapkin laboratory at the University of Pennsylvania (developed at Dana-Farber Cancer Institute) 
and human (patient tumor/ascites derived) ovarian cancer lines that can be tested as well to demonstrate 
consistency between the human and mouse (Karst et al., 2011, Karst and Drapkin, 2012). Assessing human 
derived lines would verify that NOTCH3 effects are also similar for human and mouse derived lines, 





Figure 7.3 Fallopian derived tumorigenic cell lines express varying levels of NOTCH3. (A) Mouse 
oviductal epithelial derived cell lines were assessed for the presence of NOTCH3 protein. We observed 
little to no NOTCH3 intracellular domain present on western blot for MOE PTENshRNAp53R273H. We 





In our previous experiments, we modeled the increase of Notch3 signaling by introducing the 
Notch3 ICD which may induce supra-physiological levels of Notch signaling. Conversely, it is possible that 
this level of signaling may be relevant to that seen in human ovarian cancer, that is it may resemble 
oncogenic Notch signaling. However, human patient samples generally show increase in NOTCH3 copy 
number or upregulation of full length NOTCH3 protein, which may have different properties. Therefore, one 
could further explore the effects of the Notch3 pathway in the ID8 IP2 line, in particular by examining the 
effect of overexpressing full length Notch3 (Chapter 4, Figure A4.1) to determine if activation generates 
similar results as the Notch3 ICD in increasing adhesion to collagens. One could confirm the ability of these 
lines to signal with ligand interaction, and determine if the full length NOTCH3 has a similar effect to the 
introduction of ICD. This would prove useful as ovarian cancers often upregulate full length NOTCH3, and 
would be a more physiologic representation of patient ovarian cancer. We could also investigate if Notch3 
has the same effect as upregulation of MAML. It was found in The Cancer Genome Atlas (TCGA) study 
that not only NOTCH3 was correlated with ovarian cancers, but other parts of the NOTCH3 pathway 
including MAML1, MAML2, MAML3, JAG1, and JAG2 (Cancer Genome Atlas Research, 2011). Therefore, 
it would be interesting to show that overexpression of Maml in our ID8 IP2 line also generated a similar 
effect on adhesion to extracellular matrix as Notch3. We have acquired a pFLAG-CMV-2 MAML1 construct 
which contains the human MAML1 sequence with an N-terminal FLAG-tag from the Dr. Kostandin Pajcini 
laboratory at the University of Illinois at Chicago, which could allow us to investigate whether 
overexpression of MAML has a similar effect to overexpression of Notch3.  
An important consideration for interpreting the results is the question of how significant is the trend 
toward increased peritoneal wall burden caused by Notch3 signal activation. Our analysis did not show this 
to be significantly changed but a strong trend was detected. One could replicate in vivo tumor cell 
implantation experiments and obtain higher numbers of mice to see if significance is obtained for this 
measurement. This would involve assessing for an increase of peritoneal wall and ovary tumor burden with 
Notch3 expression measured by IVIS in early stages of disease. In addition, we could assess metastatic 
spread in vivo from an orthotopic bursal injection model to examine spread from a primary to metastatic 
sites. This would be done by evaluating total bioluminescent tumor burden or the number of tumor seeds 
in the peritoneal wall. Both of these types of analysis should be done with a sufficient number of mice to 
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determine if there is a significant difference between Notch3IC and Control. This would allow us to evaluate 
the spread from the primary site and not just from the peritoneal environment, and may even reveal a more 
significant difference.  
Experiments further investigating direct attachment to the ECM of ID8 IP2 luc Notch3IC compared 
to Control may support the hypothesis of Notch3IC promoting peritoneal adhesion presented in this thesis. 
Attachment of ID8 IP2 lines to ex vivo omental explants in culture would determine if ovarian cancer cells 
attach better to target peritoneal tissue (Khan et al., 2010, Clark et al., 2013). Experiments evaluating cells 
in a 3-dimensional in vitro model, consisting of fibroblasts in a collagen I layer with an overlay of a 
mesothelial cell layer, may be used to evaluate the attachment of Notch3IC compared to Control, which 
would model attachment to exposed ECM under the mesothelium (Kenny et al., 2009). These 3D cultures 
can be evaluated histologically to determine if there is a preference for Notch3IC cells to attach to collagen 
I. The in vitro 3D models have the added advantage of replacing the need for additional lengthy mouse 
experiments for depth examination of tumor seeds. We can evaluate cells to determine if Notch3IC will 
seed at a higher ratio than Control on omentum or will attach better in the 3D model. 
There may be a role for Notch3 in allowing the survival of non-adherent cells in the peritoneal fluid 
that involves adhesion pathway genes upregulated by Notch3 activation. This is plausible since it has been 
demonstrated that integrin signaling and ECM in the ascites and within spheroids can lead to survival 
signaling for ovarian cancer cells (Brown et al., 2015, Taddei et al., 2012, Sodek et al., 2012). We could 
explore anoikis resistance of Notch3IC cells by culturing cells in non-adherent conditions and subsequently 
assessing cell survival.  
There is evidence that spheroid cancer cells demonstrate reduced proliferation, which assists these 
cancer cells in chemotherapy resistance (Sodek et al., 2012). This may explain our observation that 
Notch3IC lines subjected to FACS for selection of high Notch3 expressing cells displayed reduced 
proliferation compared to Control (Appendix Chapter 4). The reduction in proliferative ability of these cells 
may assist with chemotherapy resistance by reducing proliferation. Spheroid formation itself may shield 
cells within the spheroids from access to chemotherapy, helping cells evade death (Sodek et al., 2012). It 
has been shown ovarian cancer cells resist chemotherapy in spheroids better than the same cells in 
monolayer (L'Esperance et al., 2008). As discussed previously, spheroids may more easily form in Notch3 
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expressing tumors due to the change in adhesion and ECM pathways (Lengyel, 2010, Sodek et al., 2012). 
This hypothesis would fit with our data demonstrating high Notch3 populations of ID8 IP2 cells proliferate 
less, but there is still a reduction in survival in Notch3 expressing versus Control injected mice in vivo. We 
may want to repeat our in vitro platinum therapy experiments with ID8 IP2 Notch3IC and Control spheroids, 
to prove whether Notch3 influences chemotherapy resistance by spheroid formation of ovarian cancer cells, 
since our previous experiments only assessed cisplatin treatment of monolayers. We could assess taxane 
therapy as well, since the literature suggests Notch signaling is related to taxane resistance as well 
(Groeneweg et al., 2014a, Kang et al., 2015, Jeong et al., 2017, Hu et al., 2014). 
Lastly, we may expand our studies by evaluating other pathways influenced by Notch3 from our 
RNA-Seq data. Other pathways were identified that may be contributing to the increased ascites 
accumulation and reduced survival we observed in our in vivo studies. For example, pathways involving 
immune signaling were detected in the DAVID pathway analysis (Chapter 5), including enrichment in 
cytokine-cytokine receptor interaction and TGFβ signaling pathways (adj p = 2.57E-04, adj p = 3.66E-02, 
respectively).	 As previously mentioned, immune signaling enhances ovarian cancer cell attachment to 
metastatic sites on the peritoneal lining by retraction of mesothelial cells and exposure of the ECM (Sodek 
et al., 2012). Chemokines and cytokines have been shown to be upregulated in epithelial ovarian cancers, 
and their signaling has been implicated in cell motility and tumor angiogenesis (Freedman et al., 2004). 
TGFβ in particular has been linked to endothelial cell chemotaxis, adhesion of tumor cells, and immune 
suppression (Freedman et al., 2004, Sodek et al., 2012). Another gene significantly upregulated in our data 
that was identified in enhanced immune related pathways was the cytokine IL6 (log2 fold change 
2.173330651, adj p = 8.16E-03), which has been implicated in poor patient survival, tumor cell adhesion, 
tumor cell proliferation, and inhibition of immune cells in ovarian cancer (Freedman et al., 2004, Lane et al., 
2011). We could therefore explore experiments evaluating the presence of some of these cytokines in our 
Notch3 ID8 IP2 cells and Control, and then determine if there is an effect on tumor burden, ascites 
accumulation, and microvascular density in vivo when targeting these cytokines. Thus, there are other 
promising pathways we identified that are influenced by Notch3 that could be further investigated for their 
role in ovarian cancer progression and metastasis.  
Implications to HGSC clinical disease and therapeutics  
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We have shown Notch3 signaling influences adhesion of ovarian cancer cells to collagens I and 
IV. This may influence the initial development of metastases to the peritoneum in high grade serous ovarian 
cancer. It is thought that focusing on early, low-burden ovarian cancer detection is optimal, as treatment 
could initiate before extensive tumor spread (Cho and Shih Ie, 2009, Kurman et al., 2008). This is an 
important goal as current poor survival is associated with late stage detection of ovarian cancer and 
remaining macroscopic tumors post cytoreduction (Cho and Shih Ie, 2009, Kurman et al., 2008). This could 
include detecting low volume of disease associated with initial development of tumors and recurrent HGSC. 
Notch3 may be effecting this earlier stage of metastatic spread as demonstrated by our in vivo data analysis. 
The role of Notch3 in upregulating adhesion and ECM pathways that we have shown may affect initiation 
of tumor seeds. Upregulation of these adhesion and ECM pathways may even influence survival of ovarian 
cancer cells in the peritoneal environment before they eventually form metastases, and is consistent with 
studies described earlier in this chapter.  
Notch3 and integrin α1β1 may provide potential biomarkers for the detection of early disease or 
the beginnings of recurrent disease in patients. Evidence suggests evaluating circulating tumor DNA for 
genetic alterations in cancer, including ovarian cancers, may improve the detection and monitoring of 
disease progression (Bettegowda et al., 2014, Haber and Velculescu, 2014, Phallen et al., 2017). Because 
of the unique nature of ovarian cancer, tumor DNA may be accessible via ascites samples as well. Tumor 
DNA encoding either Notch3 or specific integrins may indicate early active metastasis or recurring disease. 
Assessment of tumor DNA could indicate which patients may benefit from potential therapeutic targeting of 
the adhesion and therefore the metastatic process in HGSC.  
Targeting of integrins that are upregulated by Notch3, such as the integrin dimer α1β1, may assist 
in reducing recurrent metastasis. Unfortunately, integrin inhibitors that have been developed for clinical use 
target integrins αvβ3, αvβ5, α5β1, and the αv and α2 subunits of dimers (Tucker, 2006, Avraamides et al., 
2008). Some integrin β1 antibodies have been effectively used to block function in ovarian cancer, and 
even reduce tumor burden in a mouse model of breast cancer (Park et al., 2006a, Casey et al., 2001, Casey 
and Skubitz, 2000). However, integrin β1 blocking antibodies have not yet been tested in the clinic. Since 
many integrin inhibitors have been able to be used clinically, it is quite plausible these integrin β1 inhibiting 
antibodies may eventually be able to be used in the clinic. Moreover, the naturally occurring collagen IV 
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derived anti-angiogenic molecule arresten is believed to function through integrin α1β1 inhibition and may 
provide a therapeutic strategy for inhibition of ovarian cancer cell metastatic adhesion (Nyberg et al., 2005, 
Colorado et al., 2000).  In addition, since arresten is an endogenous inhibitor of angiogenesis, further benefit 
may be observed on survival as is seen for the FDA approved combination treatment of ovarian cancers 
with the anti-angiogenic agent bevacizumab along with chemotherapy (McClung and Wenham, 2016, Monk 
et al., 2017, Aghajanian et al., 2012, Pujade-Lauraine et al., 2014, Coleman et al., 2017).  
The use of Notch signaling inhibitors could potentially be employed in the clinic. ᵧ -secretase 
inhibitors (GSI) have previously been used in clinical setting to inhibit Notch signaling. These would only 
target canonical Notch signaling, and Notch3 may be acting canonically and/or non-canonically. It is at least 
likely that integrins are, however, upregulated by canonical signaling, as it has been shown that Notch1 
interacts directly with the enhancers/promoters of integrin genes, so it is plausible Notch3 may as well (Hass 
et al., 2015). It is therefore possible that integrins are a direct target of Notch signaling. GSIs have been 
used in the clinic but do cause toxicity to the gastrointestinal tract and are not specific to Notch signaling, 
giving them the potential for off target effects as well (Capaccione and Pine, 2013, Groeneweg et al., 
2014b). DLL4 inhibitors have been used clinically to target tumor angiogenesis, but may not be as useful 
in the context of Notch3 pathway upregulated ovarian cancers since the major ligand interaction appears 
to be with JAGGED1 (Bellavia et al., 2008, Choi et al., 2008, Chen et al., 2010, Steg et al., 2011, 
Capaccione and Pine, 2013). The Kitajewski lab has developed Notch “decoys” that utilize the EGF-like 
repeats of Notch1 and can specifically block Jagged signaling, but these have not yet made it to the clinic 
(Kangsamaksin et al., 2015). The Kitajewski lab is, however, working on these inhibitors, and has even 
developed a Notch3 variant capable of blocking Jagged interaction as well (Kitajewski lab unpublished data, 
data not shown).  
Conclusion 
High grade serous ovarian cancer is such a deadly disease because of its ability to quickly 
metastasize before the detection of disease, and its ability to easily recur after therapy and disseminate 
into the abdominal cavity again. Metastasis in ovarian cancer occurs through shedding of cells and 
spheroids through from the primary tumor, and dissemination primarily through the peritoneal fluid or ascites 
accumulation to secondary sites on the peritoneal lining of the wall and organs. Cancer metastasis is 
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commonly thought to be a function of proliferation and stem-like characteristics of cells that can grow large 
tumor seeds. Ovarian cancer, however, is characterized by the high quantity of disseminated disease 
affecting many areas of the peritoneum. Our studies reveal insight into the important step of adhesion in 
metastasis, allowing attachment of these cancer cells to metastatic sites for the subsequent development 
of lesions. We have shown Notch3 signaling can upregulate integrin protein in an ovarian cancer model, 
ID8 IP2, and that Notch3 active lines compared to Notch3 negative lines preferentially adhere to collagen 
I, an abundant component of the peritoneum to which ovarian cancer cells are known to attach. Our insight 
into the mechanism of ovarian cancer metastasis may allow us to better understand how to target this high-
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Tables A4.1 and A4.2. Notch pathway primer sequences for primers used in Semiquantitative RT-
PCR and RT-qPCR experiments. Notch 1, 3, and 4 receptor sequences target the intracellular domain. 
(A4.1) Primer sequences for Notch receptors and ligands for RT-PCR. PCR product sizes have been 





Figure A4.1 NOTCH3 is present in ovarian cancer cell lines that are retrovirally infected with full 
length Notch3HA. (A) Western blot of NOTCH3 expression in retroviral packaging transfected GP2-293 
lines, infected ID8 IP2 luc mouse ovarian surface epithelial line (left panel), and SKOV3-IP1 human 
epithelial adenocarcinoma ascites (right panel). (B) Expression of ectopic NOTCH3 detected by staining 
western blot with HA antibody to recognize the C-terminal HA tag on NOTCH3. Expression is shown for 





Figure A4.2 Properties of ID8 IP2 luc Notch3IC and Control subjected to FACS display different 
phenotypes than for non-sorted populations of lentivirally infected cells. (A) FACS sorting of ID8 IP2 
luc based on mCherry positivity for Control (mCherry-A) and GFP positivity for Notch3IC (FITC-A). The P4 
square indicates cells collected from the sort. (B) Western blot showing the NOTCH3 expression of the 
lentiviral infected ID8 IP2 luc lines subjected to FACS. NOTCH3 intracellular domain is seen in the Notch3IC 
line but not Control or cells infected by virus generated from a pCCL GFP plasmid construct. OVCAR3 is a 
known high NOTCH3 expressing human ovarian cancer line. (C) RT-qPCR from one set of triplicates 
demonstrating the Notch3IC line subjected to FACS displays an increase in Notch3 and downstream Hey 
target transcripts. The table shows the same data of ID8 IP2 luc Notch3IC line transcript fold increase 
compared to Control. (D) FACS Notch3IC cells display a significant decrease in viability compared to 
Control p = 0.0022, Welch’s t-test). Two experiments of sextuplicate were analyzed. (E) Migration of FACS 
ID8 IP2 luc Notch3IC demonstrate a significantly increased capacity to migrate in a Scratch wounding assay 
at 3, 6 and 9 hours post monolayer disruption (p = 0.018, p = 0.041, and p = 0.038 respectively, Student’s 
t-test). Two experiments of triplicates were analyzed. (F) Survival data displaying no significant difference 
between ID8 IP2 luc Notch3IC and Control injected mice (Log-rank p = 0.5794, Gehan-Breslow-Wilcoxon 





Figure A4.3 Cachexia criteria and in vivo data analysis excluding cachectic tumor bearing mice. 
(A) Body condition score criteria. Cachexia was determined by criteria for underconditioned and 
emaciated mice. Image from (Burkholder et al., 2012). (B) Example image of a cachectic tumor bearing 
mouse at sacrifice. The table at bottom shows the number of Control and Notch3IC mice euthanized due 
to cachexia which were including in the Chapter 4 in vivo analysis. This data demonstrates that cachexia 
was not specific to either group. (C) The top graph demonstrates the percent increase in circumference 
specifically in the non-cachectic subset of the mice previously analyzed in figure 4.4B. 57 total mice were 
analyzed (29 Control, 28 Notch3IC). The bottom graph shows analysis for all mice that did not bear 
ascites. A proportion of the mice were sacrificed at the same 8-week time point; therefore, some of the 
mice that did not develop ascites may have eventually developed cachexia if allowed to survive to an 
endpoint defined as BC1, BC2, or ≥25% increase in circumference for other mice included in the study. 
Since cachexia was defined for remaining mice as having developed cachexia at all, and not necessarily 
by the 8 week time point, this analysis includes all potential cachectic mice as well. 54 total mice were 
analyzed (28 Control, 29 Notch3IC). In both cases, Notch3IC mice display a significant increase in 
circumference compared to Control (p = 0.0217, p = 0.0142, Welch’s t-test). (D) Kaplan Meier survival 
data analysis for all non-cachectic tumor bearing mice. A total of 41 mice were analyzed (21 Control, 20 
Notch3IC). The median survival for Control mice was 70 days compared to Notch3IC mice at 66 days. 
The mean survival was 73 days for Control and 65 days for Notch3IC. There was no significant difference 
in the survival between Notch3IC and Control tumor bearing mice when cachectic animals were excluded 






Figure A4.4 Peritoneal wall tumor burden, and right ovary and uterine horn tumor burden in mice 
sacrificed at 8 weeks does not show a significant difference between Notch3IC and Control despite 
higher levels of Notch3IC bioluminescent signal. (A) Peritoneal wall tumor burden measured by IVIS 
spectrum bioluminescent at the 8 week endpoint for Notch3IC and Control tumor bearing mice (p = 0.1686, 
Welch’s t-test). (B) Tumor burden by bioluminescent signal of the right ovary and right uterine horn 




Figure A5.1 Selected list of the most upregulated genes in Notch3IC compared to Control ID8 IP2 
luciferase. Heat map of genes upregulated in Notch3IC cells, with threshold criteria of adjusted p < 0.1 
and average log2 fold change ≥ 2. Samples are listed from left to right in the following order: Notch3IC Set 
# 1, Notch3IC Set #2, Notch3IC set #3, Notch3IC Set #4, Control Set #1, Control Set #2, Control Set #3, 




Figure 5.2 Selected list of the most highly downregulated genes in Notch3IC compared to Control 
ID8 IP2 luciferase. Heat map showing genes downregulated with a threshold of adjusted p < 0.1 and 













Figure A5.3 Significantly upregulated genes in adhesion and ECM pathways identified by DAVID 
pathway analysis show many integrin and collagen genes among others. This heat map displays 
upregulated genes (p >0.1, and > log2 fold) matched to significantly enriched adhesion and extracellular 
matrix pathways in DAVID pathway analysis by database. (A) Kyoto Encyclopedia of Genes and Genomes 






Table A5.1 DAVID pathway enrichment analysis of downregulated genes identified by RNA-Seq 
analysis of Notch3IC compared to Control. DAVID analysis representing the top significantly enriched 
pathways (p < 0.05) for each database assessed. Genes assessed in this pathway analysis had p <0.1 and 




Table A5.2 Adhesion pathways found to be downregulated in pathway analysis are related to cell to 
cell adhesion despite upregulation of many adhesion pathways. Since we focused on the change in 
upregulated adhesion genes from the pathway analysis, this table displays the enriched pathways related 
to adhesion that were composed of selected downregulated genes. Genes identified within these pathways 




Table A5.3 Genes identified in downregulated pathways related to adhesion. Genes with p <0.1 and 
more than a 1 log2 fold reduction in Notch3IC compared to Control identified in pathways considered 
enriched by DAVID analysis (see Table A5.2).  
Pathway
 Database Pathway Name
Gene
 Count p Value
Fold
 Enrichment
KEGG mmu00533:Glycosaminoglycan biosynthesis - keratan sulfate 3 6.23E-03 24.51
KEGG mmu04390:Hippo signaling pathway 5 3.27E-02 4.06
REACTOME Keratan sulfate biosynthesis 3 1.88E-02 13.88
GO TERM GO:0032332~positive regulation of chondrocyte differentiation 4 5.37E-04 24.60
GO TERM GO:0071312~cellular response to alkaloid 3 1.86E-03 45.09
GO TERM GO:0014824~artery smooth muscle contraction 3 2.31E-03 40.59
GO TERM GO:0030324~lung development 6 2.45E-03 6.39
GO TERM GO:0010628~positive regulation of gene expression 10 2.83E-03 3.37
Pathway
 Database Pathway Name
Gene




GO:0007156~homophilic cell adhesion via 
plasma membrane adhesion molecules 6 7.06E-03 4.98
GO TERM GO:0007155~cell adhesion 10 9.56E-03 2.79
GO TERM GO:0007159~leukocyte cell-cell adhesion 3 1.44E-02 16.23
GO TERM GO:0016337~single organismal cell-cell adhesion 4 4.62E-02 4.96
GO TERM GO:0022614~membrane to membrane docking 2 3.62E-02 54.11



















Table A5.4 GSEA top enriched pathways show a variety of pathways which includes a pathway 
related to collagen genes. This table represents the top 20 pathways determined by GSEA pathway 








 Enrichement NOM p-val
LIM_MAMMARY_LUMINAL_MATURE_DN 32 2.04 0
KEGG_LONG_TERM_DEPRESSION 21 2.03 0
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP 21 2.01 0
RADMACHER_AML_PROGNOSIS 21 1.97 1.28E-03
KEGG_ALZHEIMERS_DISEASE 23 1.94 1.22E-03
REACTOME_PLATELET_HOMEOSTASIS 23 1.93 0
BROWNE_HCMV_INFECTION_30MIN_UP 16 1.91 1.32E-03
REACTOME_SIGNALING_BY_NOTCH 23 1.90 0
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_14 41 1.89 1.16E-03
KEGG_CALCIUM_SIGNALING_PATHWAY 58 1.84 1.08E-03
MULLIGHAN_NPM1_SIGNATURE_3_UP 68 1.81 0
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP 54 1.80 0
KEGG_OLFACTORY_TRANSDUCTION 16 1.80 5.28E-03
KEGG_LONG_TERM_POTENTIATION 19 1.79 7.73E-03
HOSHIDA_LIVER_CANCER_SURVIVAL_UP 27 1.79 4.76E-03
LINDGREN_BLADDER_CANCER_CLUSTER_1_UP 17 1.73 1.05E-02
SERVITJA_LIVER_HNF1A_TARGETS_UP 33 1.73 9.56E-03
BOQUEST_STEM_CELL_UP 84 1.73 0
NABA_COLLAGENS 29 1.73 2.37E-03
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_




Table A5.5 Top enriched pathways identified by GSEA analysis of downregulated genes show 
similarity to adhesion pathways significantly enriched in DAVID analysis for Notch3 intracellular 
domain regulated genes. The table shows top the 20 pathways enriched from GSEA assessment of genes 
with adjusted p < 0.1 and average log2 fold change ≤ -1 for Notch3IC compared to Control. While enriched 
adhesion pathways identified by GSEA are similar to adhesion pathways identified by DAVID, these 








HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN 16 0 -2.07
GAJATE_RESPONSE_TO_TRABECTEDIN_UP 16 3.85E-03 -2.06
REACTOME_CELL_JUNCTION_ORGANIZATION 26 1.10E-02 -1.84
REACTOME_RNA_POL_I_PROMOTER_OPENING 19 1.99E-02 -1.83
REACTOME_MEIOTIC_RECOMBINATION 21 9.01E-03 -1.79
GOZGIT_ESR1_TARGETS_UP 35 6.85E-03 -1.70
GOLDRATH_HOMEOSTATIC_PROLIFERATION 36 1.64E-02 -1.69
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION 27 1.70E-02 -1.68
REACTOME_RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_
TRANSCRIPTION 22 1.03E-02 -1.68
HOLLMANN_APOPTOSIS_VIA_CD40_UP 35 2.55E-02 -1.66
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_UP 16 2.03E-02 -1.66
MCCLUNG_COCAINE_REWARD_5D 18 1.38E-02 -1.64
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 21 3.29E-02 -1.62
KANG_IMMORTALIZED_BY_TERT_UP 23 1.98E-02 -1.61
BOYLAN_MULTIPLE_MYELOMA_PCA3_UP 17 2.44E-02 -1.61
REACTOME_PHASE_II_CONJUGATION 15 4.12E-02 -1.61
KIM_MYCN_AMPLIFICATION_TARGETS_DN 17 2.89E-02 -1.59
NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_DN 28 1.84E-02 -1.58
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP 24 2.91E-02 -1.58




Table A5.6 Collagen genes are found to be enriched in GSEA analysis of Notch3 intracellular domain 
regulated genes. Chart displaying each collagen gene in the pathway for enrichment in the significantly 












Col16a1 6 9.23 0.172 Yes
Col19a1 71 4.48 0.238 Yes
Col6a1 72 4.42 0.321 Yes
Col15a1 100 3.89 0.386 Yes
Col2a1 209 2.84 0.408 Yes
Col6a5 298 2.41 0.427 Yes
Col24a1 434 1.94 0.424 Yes
Col4a2 499 1.82 0.440 Yes
Col6a3 543 1.75 0.460 Yes
Col8a2 772 1.39 0.419 Yes
Col4a3 774 1.39 0.445 Yes
Col27a1 839 1.30 0.451 Yes
Col4a1 861 1.28 0.469 Yes
Col6a6 898 1.24 0.481 Yes
Col6a2 959 1.17 0.486 Yes
Col20a1 1008 1.13 0.493 Yes
Col5a2 1107 1.03 0.484 Yes
Col18a1 1128 1.01 0.497 Yes
Col1a2 1156 0.99 0.507 Yes
Col28a1 1188 0.96 0.516 Yes
Col23a1 1311 0.87 0.497 No
Col8a1 1498 0.75 0.456 No
Col3a1 1594 0.70 0.442 No
Col13a1 1810 0.59 0.390 No
Col11a1 1905 0.56 0.372 No
Col11a2 1939 0.54 0.373 No
Col5a1 2465 -0.69 0.231 No
Col7a1 2920 -1.10 0.119 No




Figure A5.4 GSEA assessment identifies the NABA_COLLAGENS pathway as enriched in RNA-Seq 
analysis of Notch3 intracellular domain regulated genes. From pathway analysis of log2 fold change of 
genes the NABA_COLLAGENS pathway was the most significantly upregulated adhesion pathway. This 
figure shows the graphs generated in the pathway analysis for comparison of RNA-Seq data from GSEA 
for NABA_COLLAGENS. (A) Image displays the enrichment plot (B) Panel shows the enrichment score 






Figure A6.1 ID8 IP2 luciferase lines are differentially adherent to distinct extracellular matrices.  
(A) Average counts of cells adhered to plates coated with the indicated ECM using 3 sets of ID8 IP2 
luciferase Notch3IC and Control infected cells. Averages for each cell line (a biological replicate) were 
generated from 3-4 experiments of triplicates, and averages for the 3 biological replicates were plotted. 
Laminin, fibronectin, and vitronectin experiments were completed by plating 2x104 cells per well, and cells 
were allowed to adhere for 30 minutes. Collagen I and collagen IV, designated with asterisks, were 
completed by seeding 2x104 cells per well which were allowed to adhere for a total of 90 minutes. This 
increase in seeding time was designed to compensate for the overall lower levels of adherence to collagen 




Figure A6.2 ITGA1 antibody blocking does not affect adhesion to collagens I and IV.  
(A) The ratio of Notch3IC cells adhered to collagen I compared to Control is similar for cells treated with 
ITGA1 blocking antibody versus isotype control, indicating that the increased adhesion of Notch3IC cells is 
not altered by blocking ITGA1 (p = 0.7652, Welch’s t-test). Cells were treated with 10μg/mL of ITGA1 
antibody or isotype control antibody. (B) IGTA1 blocking antibody also does not significantly alter the ratios 
of adherent cells on collagen IV (p = 0.6686, Welch’s t-test)  
